WO2010008084A1 - 糖鎖認識受容体の新規用途 - Google Patents
糖鎖認識受容体の新規用途 Download PDFInfo
- Publication number
- WO2010008084A1 WO2010008084A1 PCT/JP2009/063008 JP2009063008W WO2010008084A1 WO 2010008084 A1 WO2010008084 A1 WO 2010008084A1 JP 2009063008 W JP2009063008 W JP 2009063008W WO 2010008084 A1 WO2010008084 A1 WO 2010008084A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mincle
- sap130
- fcrγ
- substance
- cells
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
Definitions
- the present invention relates to a novel use of Mincle (Macrophage inducible C-type lectin) known as a sugar chain recognition receptor. Specifically, the present invention suppresses the inflammatory response by inhibiting Mincle expression or function (protein or Fc receptor common ⁇ subunit (FcR ⁇ ) released from non-homeostatic dead cells).
- Mincle expression or function protein or Fc receptor common ⁇ subunit (FcR ⁇ ) released from non-homeostatic dead cells.
- Non-patent Document 1 In physiologically programmed cell death, in contrast to sputum that is rapidly swallowed and digested by phagocytic cells without inducing inflammation (Non-patent Document 1) sputum, non-irradiation, tissue damage, etc. Excessive or non-constant cell death caused by infectious stimuli induces transient infiltration of tissue by neutrophils (Non-patent Document 2). The molecular mechanisms by which cells recognize this excess or non-homeostatic cell death and respond appropriately are not well understood.
- TLR Toll-like receptor family of innate immune receptors include DNA / RNA-protein complexes such as hyaluronan, heat shock protein ⁇ (HSPs), uric acid, fibronectin, cardiolipin, and nucleosomes and small nuclear ribonucleoprotein (snRNPs) Have been reported to recognize self-ligands released from dead cells (Non-patent Document 3). Some of these TLR-self-ligand interactions have been shown to be involved in inflammatory diseases.
- HSPs heat shock protein ⁇
- uric acid uric acid
- fibronectin fibronectin
- cardiolipin cardiolipin
- snRNPs small nuclear ribonucleoprotein
- C-type lectins are a different family of receptors than TLRs, but may be involved in sensing dead cells. These receptors have a clear role in immunity as pattern recognition receptors (PRR) ⁇ of pathogen sugar chains. Furthermore, recent evidence suggests that they can also recognize ligands such as proteins, fats and minerals. In addition to acting as a PRR, some of the C-type lectins expressed in myeloid cells should also function as receptors for dead cells (Non-patent Document 4). Many of them are phagocytic receptors that promote the clearing of dead cells.
- PRR pattern recognition receptors
- Mincle also known as Clec4e or Clecsf9
- C / EBP ⁇ transcription factor NF-IL6
- the object of the present invention is a novel molecule involved in the mechanism of recognizing unprogrammed, excessive or non-homeostatic cell death and eliciting an inflammatory response, in particular a receptor molecule that recognizes a self-ligand released from dead cells And providing a novel means of modulating the inflammatory response by modulating signal transduction through the ligand-receptor interaction.
- Another object of the present invention is to identify Mincle's physiological ligand and elucidate its physiological function.
- Mincle selectively associates with FcR ⁇ and activates macrophages to produce inflammatory cytokines / chemokines, and the receptor is derived from dead cells. It was found that it recognizes a 130 kDa protein (SAP130; also called “Sf3b3”) that is a component of the released small nuclear ribonucleoprotein. Furthermore, in mice in which thymocyte death was induced by irradiation, it was found that neutrophil infiltration into the thymus was inhibited by administration of anti-Mincle antibody, and the anti-inflammatory effect due to in vivo Mincle suppression was confirmed. As a result of further studies based on these findings, the present inventors have completed the present invention.
- SAP130 also called “Sf3b3”
- an anti-inflammatory agent comprising a substance that inhibits the expression of Mincle or the interaction between Mincle and SAP130 or FcR ⁇ .
- the agent according to [1], wherein the substance that inhibits the interaction between Mincle and SAP130 is an antibody against Mincle.
- the substance that inhibits the interaction between Mincle and SAP130 is the amino acid sequence represented by amino acid numbers 146 to 150 in the amino acid sequence of human Mincle represented by SEQ ID NO: 2 or the corresponding amino acid in an ortholog of other mammals
- the agent according to [1] which is a peptide comprising a sequence.
- the agent according to [1], wherein the substance that inhibits the interaction between Mincle and SAP130 is an antibody against SAP130.
- the agent according to [1], wherein the substance that inhibits Mincle expression is an antisense nucleic acid, ribozyme or siRNA against the Mincle gene.
- [10] Contact Mincle or a fragment containing its extracellular region with SAP130 in the presence and absence of the test substance, and compare the degree of interaction between Mincle or its fragment and SAP130 under both conditions
- a screening method for a substance that modulates an inflammatory response characterized by comprising: [11] Measure the degree of interaction between Mincle or a fragment thereof and FcR ⁇ in a cell expressing Mincle or a fragment containing the extracellular and transmembrane region thereof and FcR ⁇ in the presence or absence of the test substance
- a method for screening a substance that modulates an inflammatory response comprising comparing the substances.
- a screening method for a substance that regulates an inflammatory reaction comprising measuring and comparing the amount of the protein or mRNA encoding the protein in Mincle-producing cells in the presence and absence of a test substance .
- a method for detecting non-homeostatic cell death comprising measuring the amount of SAP130 in a sample collected from a test animal.
- Mincle or the interaction between Mincle and SAP130 or FcR ⁇ By inhibiting the expression of Mincle or the interaction between Mincle and SAP130 or FcR ⁇ , it is possible to block FcR ⁇ -dependent signal transduction and prevent the inflammatory response stimulated by non-homeostatic cell death.
- a substance having an action of regulating an inflammatory reaction can be selected using the effect on the interaction between Mincle and SAP130 or FcR ⁇ as an index.
- non-homeostatic cell death can be detected using the release of SAP130 outside the cell as an index.
- Each peptide was coated at 0.5 nM on a microplate coated with streptavidin. After blocking with BSA, rIgG, anti-Mincle monoclonal antibody and anti-rat IgG-HRP were used as primary and secondary, respectively.
- the deduced epitope sequences (VEGQW for 1B6 and FWD for 4A9) are shown, respectively.
- Mincle R 42 is important for binding to FcR ⁇ .
- 293T cells were transfected with Flag-tagged Mincle wild type and Mincle R 42 I along with FcR ⁇ . Lysates were immunoprecipitated with anti-FcR ⁇ (upper panel) or anti-Flag (lower panel) and blotted with the indicated antibodies.
- Mincle R 42 is important for signal transduction ability. 2B4 T cells were transfected with Flagc-tagged Mincle wild type and Mincle R42I with FcR ⁇ . Cells were stimulated with plate-coated anti-Flag and IL-2 production was measured by ELISA. Data are representative of 3 separate experiments. (a) Production of TNF ⁇ and MIP-2 upon Mincle ligation.
- Peritoneal macrophages induced with thioglycolic acid were stimulated with rat IgG1 (rIgG1) or anti-Mincle monoclonal antibody (6E2) coated on the plate for 18 hours, and cytokine production in the culture supernatant was determined by ELISA. Similar results were obtained with other anti-Mincle monoclonal antibody clones 1B6 and 4A9.
- Mincle-induced activation is FcR ⁇ -dependent.
- MIP-2 production by stimulation with thioglycolic acid-induced anti-Mincle monoclonal antibody (6E2) or 100 ⁇ g / ml Zymosan coated with peritoneal macrophages from wild-type, FcR ⁇ -/- and MyD88 -/- mice was determined by ELISA.
- Macrophages derived from thioglycolic acid-induced Fc ⁇ RI / III-deficient and FcR ⁇ -deficient mice were stimulated for 5 minutes as in (c) and blotted with anti-phosphotyrosine (pY) and anti-phospho-Erk.
- Bone marrow derived macrophages (left panel) were left unstimulated or stimulated with 1 ng / ml LPS for 18 hours. Cells were stained with biotinylated rat IgG1-bio (rIgG) and biotinylated anti-Mincle (1B6), and Streptavidine-APC (right panel).
- rIgG biotinylated rat IgG1-bio
- 1B6 biotinylated anti-Mincle
- Streptavidine-APC (b) NFAT-GFP activation by immobilized anti-Mincle. 2B4 cells expressing NFAT-GFP were transfected with FcR ⁇ and / or Mincle.
- NFAT reporter cells expressing Mincle and FcR ⁇ were cultured in the presence or absence of 10 ⁇ g / ml rat IgG1 (rIgG), anti-Mincle clone 1B6 (1B6), or anti-Mincle clone 4A9 (4A9) without media change for the indicated times .
- GFP expression in two replicate tests was analyzed by flow cytometry for the indicated times. Data show representative examples of 3 separate experiments.
- Mincle wild type (WT), Mincle E169Q / N171D (EPN-> QPD) and Mincle ⁇ VEGQW ( ⁇ VEGQW) were expressed in NFAT-GFP reporter cells together with FcR ⁇ . Cells were treated as in (b) and GFP expression was determined by flow cytometry.
- TM transmembrane.
- CLD C-type lectin domain.
- Ig-Mincle selectively recognizes dead cells.
- Thymocytes were treated with 10 ⁇ M dexamethasone for 4 hours and stained with Ig or Ig-Mincle and APC-labeled anti-hIgG. Cells were also stained with AnnexinV-FITC (AnV) and propidium iodide (PI).
- p130 interacts specifically with Mincle. 2B4 dead cells were lysed and subsequently pulled down with free (-), Ig-bound (Ig) and Ig-Mincle-bound (Ig-Mincle) Protein G Sepharose and analyzed by silver staining.
- p130 was identified as SAP130. The sequence of 10 independent peptides was analyzed by mass spectrometry (left).
- the digested peptides were analyzed by MALDI-TOF / MS (matrix-assisted-laser-desorption / ionization-time-of-flight-mass-spectrometry).
- p130 was identified as SAP130. The peptide-derived sequence was superimposed on the entire amino acid sequence of SAP130.
- SAP130-V5 induces MIP-2 production in macrophages. V130-tagged SAP130 was transfected into 293T cells. Cell lysate was applied to an anti-V5 agarose column and the bound protein was eluted with V5 peptide.
- SAP130-V5 induces cell activation through Mincle.
- NFAT reporter cells expressing either FcR ⁇ alone or both Mincle and FcR ⁇ were stimulated with recombinant V5-tagged SAP130 for 18 hours in the presence or absence of 10 ⁇ g / ml anti-Mincle (1B6) on anti-V5 coated plates.
- the IL-2 concentration in the culture supernatant was determined by ELISA.
- HN-tagged SAP130 was purified from Sf9 cells using Q-Sepharose and TALON columns. The purified protein was separated by SDS-PAGE and confirmed by silver staining (lane 1) and anti-SAP130 blot. Macrophages induced with thioglycolic acid were stimulated with 0.5 ⁇ g / ml recombinant HN-tagged SAP130 (SAP130-HN) and 1 ng / ml LPS for 6 hours, and MIP-2 production was determined by ELISA (right panel). (a) TUNEL staining of thymus from untreated and 1-Gy irradiated mice (GammaCell, MDS Nordion).
- a-b 500 ⁇ g of anti-Mincle (1B6) was intravenously administered to B6 mice. After 1 hour, 10 ⁇ g LPS was injected intraperitoneally, and at 20 hours, peritoneal cells were collected and analyzed. The percentage (a) and absolute number (b) of neutrophils in peritoneal cells are shown. Each group contains at least 4 mice.
- CMFDA 5-chloromethylfluorescein diacetate
- the U2 snRNP complex consists of SF3b, SF3a, Sm, U2A 'and U2B'. SAP49, SAP130, SAP145, SAP155 and snRNA form SF3b.
- the GUAGUA sequence in U2 snRNA is well conserved among species and pairs with sequences around branch points in introns.
- the sample described in Fig. 4a was pulled down with Ig-Mincle and ProteinG Sepharose and blotted with antibodies such as anti-SAP49, anti-SAP145 and anti-SAP155 against U2 snRNP complex protein.
- “Mincle”, “SAP130” and “FcR ⁇ ” in the present invention are proteins comprising the same or substantially the same amino acid sequence as the amino acid sequences represented by SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6, respectively. It is. In the present specification, proteins and peptides are described with the N-terminus (amino terminus) at the left end and the C-terminus (carboxyl terminus) at the right end according to the convention of peptide designation.
- proteins can be found in cells of humans and other warm-blooded animals (eg, guinea pigs, rats, mice, chickens, rabbits, dogs, pigs, sheep, cows, monkeys, etc.) [eg, hepatocytes, spleen cells, neurons, Glial cells, pancreatic beta cells, bone marrow cells, mesangial cells, Langerhans cells, epidermal cells, epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibroblasts, fibrocytes, muscle cells, adipocytes, immune cells (eg, Macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells, osteoblasts, osteoclasts Cells, breast cells or stromal cells, or precursor cells of these cells, stem cells, cancer cells, etc.] or any tissue in which
- amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: n 2, 4 or 6)
- amino acid sequence represented by SEQ ID NO: n is about 60% or more, preferably Examples include amino acid sequences having similarity of about 70% or more, more preferably about 80% or more, more preferably about 90% or more, particularly preferably about 95% or more, and most preferably about 97% or more.
- similarity refers to an optimal alignment when two amino acid sequences are aligned using a mathematical algorithm known in the art (preferably, the algorithm uses a sequence of sequences for optimal alignment). The percentage of identical and similar amino acid residues relative to all overlapping amino acid residues in which one or both of the gaps can be considered).
- Similar amino acids means amino acids that are similar in physicochemical properties, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn). ), Basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), amino acids with small side chains (Gly, Ala, Ser, Thr, Met), etc. Examples include amino acids classified into groups. It is expected that substitution with such similar amino acids will not change the phenotype of the protein (ie, is a conservative amino acid substitution). Examples of conservative amino acid substitutions are well known in the art and are described in various literature (see, for example, Bowie et al., Science, 247: 1306-1310 (1990)).
- the amino acid sequence substantially the same as the amino acid sequence represented by SEQ ID NO: n is about 60% or more, preferably about 70% or more, more preferably the amino acid sequence represented by SEQ ID NO: n. Is an amino acid sequence having about 80% or more, more preferably about 90% or more, particularly preferably about 95% or more, and most preferably about 97% or more.
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: n includes an amino acid sequence substantially the same as the amino acid sequence represented by SEQ ID NO: n No .: A protein having substantially the same activity as the protein consisting of the amino acid sequence represented by n.
- activity refers to the activity of interacting with SAP130 in the case of Mincle and inducing the production of inflammatory cytokines, etc. via FcR ⁇ , and the activity of transporting neutrophils. This refers to the ability to interact and activate Mincle. In the case of FcR ⁇ , it refers to the activity of inducing production of inflammatory cytokines etc. coupled to Mincle and the activity of transporting neutrophils.
- substantially the same quality means that the properties are qualitatively the same, for example, physiologically or pharmacologically. Accordingly, the activities are preferably equivalent, but the degree of these activities (eg, about 0.01 to about 100 times, preferably about 0.1 to about 10 times, more preferably 0.5 to 2 times), the molecular weight of the protein Quantitative factors such as may be different.
- the interaction between Mincle and SAP130, Mincle and FcR ⁇ , and neutrophil transport activity can be performed according to a method known per se, for example, according to the method described in Examples below.
- the Mincle in the present invention has one or more amino acid sequences represented by SEQ ID NO: 2 (for example, about 1-30, preferably about 1-10, more preferably 1-number (5, Also included are so-called muteins such as proteins containing amino acid sequences in which 4, 3 or 2) amino acids have been substituted, deleted, inserted or added (or a combination thereof).
- SEQ ID NO: 2 for example, about 1-30, preferably about 1-10, more preferably 1-number
- muteins such as proteins containing amino acid sequences in which 4, 3 or 2) amino acids have been substituted, deleted, inserted or added (or a combination thereof).
- SAP130 in the present invention contains 1 or 2 or more (for example, about 1-50, preferably about 1-30, more preferably about 1-10) in the amino acid sequence represented by SEQ ID NO: 4.
- FcR ⁇ has 1 or 2 or more (for example, about 1 to 30, preferably about 1 to 10, more preferably 1) in the amino acid sequence represented by SEQ ID NO: 6. Also included are proteins containing amino acid sequences in which up to several (5, 4, 3 or 2) amino acids have been substituted, deleted, inserted or added (or combinations thereof).
- Mincle As another preferable example of Mincle, SAP130 and FcR ⁇ protein in the present invention, various splicing variants (for example, in the case of Mincle, GeneCards (registered trademark) Alternative Splicing Database (ASD)) Supplice Patterns (SP) 1 to SP5 for CLEC4E Human Mincle splicing variants, etc.
- GeneCards registered trademark
- ASD Alternative Splicing Database
- SP Supplice Patterns
- SAP130 ASD is registered as SP1 to SP13 related to SF3B3 in the ASD;
- FcR ⁇ is registered as SP1 to SP2 related to FCER1G, in the case of FcR ⁇ Human SAP130 splicing variants, etc., or their orthologs in other mammals (for example, in the case of Mincle, mouse orthologs registered in GenBank as RefSeq No.06NP_064332, rat orthologs registered as RefSeq No. NP_001005897, RefSeq Registered as No. XP_001135204 Chimpanzee orthologs, dog orthologs registered as RefSeq No.
- the ⁇ substance that inhibits the interaction between Mincle and SAP130 '' may be any substance that can inhibit Mincle activation by coupling with FcR ⁇ and inhibit the transmission of a signal by coupling with FcR ⁇ . Include substances that inhibit the binding between Mincle and SAP130.
- examples of the substance that inhibits the binding between Mincle and SAP130 include antibodies against Mincle or SAP130 protein.
- the antibody may be a polyclonal antibody or a monoclonal antibody. These antibodies can be produced according to per se known antibody or antiserum production methods.
- the isotype of the antibody is not particularly limited, but preferably IgG, IgM or IgA, particularly preferably IgG.
- the antibody is not particularly limited as long as it has at least a complementarity determining region (CDR) for specifically recognizing and binding a target antigen.
- CDR complementarity determining region
- Fab, Fab ′, F (ab ') 2 such as fragments, scFv, scFv-Fc, conjugation molecules prepared by genetic engineering such as minibodies and diabodies, or molecules having protein stabilizing action such as polyethylene glycol (PEG) They may be modified derivatives thereof.
- Mincle is a single-transmembrane cell surface receptor
- the anti-Mincle antibody in the present invention recognizes the extracellular region of Mincle.
- the Mincle region important for interaction with SAP130 is VEGQW represented by amino acid numbers 146 to 150 in the amino acid sequence represented by SEQ ID NO: 2 (SEQ ID NO: 7) (in other mammalian orthologs, the corresponding amino acid sequence). Therefore, the anti-Mincle antibody in the present invention preferably recognizes the region.
- Such an antibody is prepared by synthesizing an oligopeptide containing the amino acid sequence of the region using a well-known peptide synthesis method such as a solid phase synthesis method and combining it with an appropriate carrier protein as an immunogen. Or by in vitro immunization using lymphocytes or the like.
- a well-known peptide synthesis method such as a solid phase synthesis method
- the binding of the antibody inhibits SAP130 from binding to Mincle and activating it. As long as it can, it can be preferably used similarly.
- the anti-SAP130 antibody in the present invention may recognize any region of SAP130, but is preferably important for interaction with Mincle.
- Binding to the Mincle region particularly the region containing the corresponding amino acid sequence in VEGQW (SEQ ID NO: 7) represented by amino acid numbers 146 to 150 in the amino acid sequence represented by SEQ ID NO: 2 or other mammalian orthologs And an antibody that recognizes a region involved in.
- an antibody against Mincle or SAP130 protein is used as a pharmaceutical for human administration
- the antibody preferably a monoclonal antibody
- the antibody has a reduced risk of showing antigenicity when administered to a human.
- Antibodies specifically, fully human antibodies, humanized antibodies, mouse-human chimeric antibodies and the like, particularly preferably fully human antibodies.
- Humanized antibodies and chimeric antibodies can be produced by genetic engineering according to conventional methods.
- fully human antibodies can be produced from human-human (or mouse) hybridomas, but in order to provide a large amount of antibodies stably and at low cost, human antibody-producing mice and phage display methods are used. It is desirable to manufacture using.
- an example of another substance that inhibits the binding between Mincle and SAP130 is a peptide containing an amino acid sequence that is the same as or substantially the same as the amino acid sequence of the region involved in the binding of Mincle to SAP130.
- the “substantially identical amino acid sequence” means that 1 to 3, preferably 1 to 2 amino acids are substituted, deleted, inserted or added in the amino acid sequence of the region involved in binding to SAP130. Means a sequence that retains the binding ability to SAP130.
- the amino acid sequence of the region involved in the binding of Mincle to SAP130 includes VEGQW (SEQ ID NO: 7) represented by amino acid numbers 146 to 150 in the amino acid sequence of human Mincle represented by SEQ ID NO: 2 described above.
- the length of the peptide is not particularly limited, but considering the molecular weight, ease of synthesis, antigenicity problems, etc., it is about 5-50 amino acids, preferably about 5-30 amino acids, more preferably 5-15. About amino acids.
- the peptide may contain an amino acid sequence that does not participate in binding to SAP130.
- the peptide may have a physicochemical property (as long as it does not adversely affect the interaction between the amino acid sequence involved in binding and SAP130.
- Amino acid sequences designed to improve eg, hydrophobicity, isoelectric point, thermal stability, pH stability, enzyme stability, etc.
- the N-terminus and / or C of the amino acid sequence involved in the binding Can be added to the end.
- the substance that inhibits the interaction between Mincle and SAP130 in the present invention is not limited to the anti-Mincle antibody and SAP130-binding peptide as described above, as long as it directly or indirectly inhibits the interaction between Mincle and SAP130.
- Other substances such as low molecular weight compounds may also be used.
- Such a substance can be obtained, for example, by the screening method (I) or (III) of the present invention described later.
- the “substance inhibiting Mincle expression” may act at any stage such as the Mincle gene transcription level, post-transcriptional regulation level, protein translation level, post-translational modification level, etc. Good. Therefore, substances that inhibit Mincle protein expression include, for example, substances that inhibit Mincle gene transcription, substances that inhibit the processing of early transcripts into mRNA, substances that inhibit mRNA transport to the cytoplasm, and mRNA Examples include substances that promote degradation, substances that inhibit translation of mRNA into protein, and substances that inhibit post-translational modification of Mincle polypeptide.
- the substance capable of specifically inhibiting the translation of Mincle mRNA into protein preferably includes a nucleic acid containing a base sequence complementary to or substantially complementary to the base sequence of these mRNAs or a part thereof.
- a base sequence substantially complementary to the base sequence of Mincle mRNA is a base having a degree of complementarity capable of binding to the target sequence of the mRNA and inhibiting its translation under physiological conditions in mammalian cells.
- the base sequence complementary or substantially complementary to the base sequence of Mincle mRNA includes (a) the base sequence represented by SEQ ID NO: 1 or (b) conditions that are stringent with the base sequence.
- substantially the same quality of activity has the same meaning as described above.
- the stringent conditions are, for example, the conditions described in Current Protocols in Molecular Biology, John Wiley & Sons, 6.3.1-6.3.6, 1999, such as 6 ⁇ SSC (sodium chloride / sodium citrate) / 45 Hybridization at 0.2 ° C., followed by one or more washings at 0.2 ⁇ SSC / 0.1% SDS / 50 to 65 ° C., and those skilled in the art will be familiar with hybridization conditions that give equivalent stringency. Can be appropriately selected.
- Mincle mRNA is preferably registered as human Mincle mRNA (RefSeq Accession No. NM_014358) containing the base sequence represented by SEQ ID NO: 1, or their orthologs in other mammals (for example, RefSeq No. NM_019948 in GenBank).
- a part of a base sequence complementary or substantially complementary to the base sequence of Mincle mRNA is capable of specifically binding to Mincle mRNA and inhibiting the translation of a protein from the mRNA. If so, the length and position are not particularly limited, but from the viewpoint of sequence specificity, a portion complementary or substantially complementary to the target sequence is at least 10 bases or more, preferably about 15 bases or more, more preferably Contains about 20 bases or more.
- nucleic acid comprising a base sequence complementary to or substantially complementary to the base sequence of Mincle mRNA or a part thereof include any of the following (a) to (c): .
- (a) Antisense nucleic acid against Mincle mRNA b) siRNA against Mincle mRNA
- the “antisense nucleic acid against Mincle mRNA” in the present invention is a nucleic acid containing a base sequence complementary to or substantially complementary to the base sequence of the mRNA, or a part thereof, and specific and stable with the target mRNA. It has a function of suppressing protein synthesis by forming a double chain and binding.
- the antisense nucleic acid may be a double-stranded DNA, a single-stranded DNA, a double-stranded RNA, a single-stranded RNA, a DNA: RNA hybrid, or may be one with a known modification added.
- the “nucleic acid” may contain not only purine and pyrimidine bases but also those having other modified heterocyclic bases.
- the RNA DNA hybrid formed by the target RNA and the antisense DNA can be recognized by the endogenous RNase H and cause selective degradation of the target RNA. Therefore, in the case of antisense DNA directed to degradation by RNase H, the target sequence may be not only the sequence in mRNA but also the sequence of the intron region in the initial translation product of CPSF5 or CPSF6 gene. Furthermore, the antisense nucleic acid of the present invention may be one that binds to Mincle gene, which is a double-stranded DNA, to form a triplex (triplex) and can inhibit transcription to RNA (antigene). .
- the length of the target region of the antisense nucleic acid of the present invention is not particularly limited as long as the antisense nucleic acid hybridizes, and as a result, the translation into Mincle protein is inhibited.
- the entire sequence of mRNA or initial transcription product can be mentioned as long as about 10 bases.
- an oligonucleotide consisting of about 10 to about 40 bases, particularly about 15 to about 30 bases is preferred, but is not limited thereto.
- the nucleotide molecule constituting the antisense nucleic acid may be natural DNA or RNA, but various chemicals may be used to improve stability (chemical and / or enzyme) and specific activity (affinity with RNA). Modifications can be included. For example, in order to prevent degradation by nuclease, etc., phosphate residues (phosphate) of each nucleotide constituting the antisense nucleic acid, for example, chemically modified phosphate residues such as phosphorothioate (PS), methylphosphonate, phosphorodithionate, etc. Can be substituted.
- PS phosphorothioate
- methylphosphonate methylphosphonate
- phosphorodithionate etc.
- the 2′-position hydroxyl group of the sugar (ribose) of each nucleotide is represented by —OR (R is, for example, CH 3 (2′-O-Me), CH 2 CH 2 OCH 3 (2′-O-MOE), CH 2 CH 2 NHC (NH) NH 2 , CH 2 CONHCH 3 , CH 2 CH 2 CN and the like may be substituted).
- R is, for example, CH 3 (2′-O-Me), CH 2 CH 2 OCH 3 (2′-O-MOE), CH 2 CH 2 NHC (NH) NH 2 , CH 2 CONHCH 3 , CH 2 CH 2 CN and the like may be substituted).
- the base moiety pyrimidine, purine
- BNA LNA
- ENA ENA
- the antisense oligonucleotide of the present invention determines the target sequence based on the Mincle cDNA sequence or genomic DNA sequence, and uses a commercially available DNA / RNA automatic synthesizer (Applied Biosystems, Beckman, etc.) It can be prepared by synthesizing complementary sequences.
- siRNA double-stranded RNA consisting of oligo RNA complementary to Mincle mRNA and its complementary strand
- siRNA is also complementary to or substantially complementary to the base sequence of Mincle mRNA or a nucleotide sequence thereof. Defined as encompassed by a portion of nucleic acid.
- siRNA can be appropriately designed using commercially available software (eg, RNAi Designer; Invitrogen) based on the base sequence information of the target mRNA.
- the ribonucleoside molecule constituting siRNA may also be modified in the same manner as the above-described antisense nucleic acid in order to improve stability, specific activity and the like.
- siRNA if all ribonucleoside molecules in natural RNA are replaced with a modified form, RNAi activity may be lost, so the introduction of the minimum modified nucleoside that allows the RISC complex to function is necessary.
- the siRNA is synthesized by synthesizing the sense strand and antisense strand of the target sequence on the mRNA with a DNA / RNA automatic synthesizer and denatured in an appropriate annealing buffer at about 90 to about 95 ° C. for about 1 minute, It can be prepared by annealing at about 30 to about 70 ° C. for about 1 to about 8 hours. Alternatively, it can be prepared by synthesizing a short hairpin RNA (shRNA) that is a precursor of siRNA and cleaving it with a dicer.
- shRNA short hairpin RNA
- Examples of the nucleic acid designed so that siRNA against Mincle mRNA can be generated in vivo include the above-mentioned shRNA and an expression vector constructed so as to express it.
- shRNA is an oligo containing a base sequence in which the sense and antisense strands of the target sequence on mRNA are linked by inserting a spacer sequence (for example, about 15 to 25 bases) long enough to form an appropriate loop structure. It can be prepared by designing RNA and synthesizing it with an automatic DNA / RNA synthesizer.
- An expression vector containing an shRNA expression cassette can be prepared by preparing a double-stranded DNA encoding the above shRNA by a conventional method and then inserting it into an appropriate expression vector.
- an shRNA expression vector one having a Pol III promoter such as U6 or H1 can be used.
- the shRNA transcribed in the animal cell into which the expression vector has been introduced forms a loop by itself, and then is processed by an endogenous enzyme dicer or the like to form a mature siRNA.
- nucleic acid containing a base sequence complementary to or substantially complementary to the base sequence of Mincle mRNA or a part thereof is a ribozyme capable of specifically cleaving the mRNA within the coding region.
- ribozyme is used as a concept including DNA as long as it has sequence-specific nucleic acid cleavage activity.
- the most versatile ribozyme is self-splicing RNA found in infectious RNA such as viroid and virusoid, and the hammerhead type and hairpin type are known.
- Nucleic acid containing a base sequence complementary to or substantially complementary to the base sequence of Mincle mRNA or a part thereof is provided in a special form such as a liposome or a microsphere, or a polycationic body such as polylysine or a lipid.
- a hydrophobic substance such as (eg, phospholipid, cholesterol, etc.) can be provided in an added form.
- the substance that inhibits Mincle expression in the present invention is not limited to the antisense nucleic acid, siRNA, ribozyme and the like as described above, and other substances such as low molecular weight compounds can be used as long as they inhibit Mincle expression directly or indirectly. It may be a substance. Such a substance can be obtained, for example, by the screening method (IV) of the present invention described later.
- the “substance that inhibits the interaction between Mincle and FcR ⁇ ” may be any substance that can inhibit the activated Mincle from coupling with FcR ⁇ and transmitting a signal. And a substance that inhibits the association of FcR ⁇ .
- examples of the substance that inhibits the association between Mincle and FcR ⁇ include antibodies against Mincle and / or FcR ⁇ .
- An antibody against Mincle or FcR ⁇ may reduce the ability to associate with a partner by binding to Mincle or FcR ⁇ , thereby sterically inhibiting association with a partner molecule or causing a conformational change, respectively.
- Bispecific antibodies that recognize Mincle and FcR ⁇ also block FcR ⁇ -mediated signaling if they bind to both antigen molecules and become inaccessible to the extent that they can interact. Therefore, it can be preferably used similarly.
- the Mincle and FcR ⁇ regions recognized by these antibodies are not particularly limited, but are preferably extracellular regions.
- the antibody against Mincle and / or FcR ⁇ may be a polyclonal antibody or a monoclonal antibody. These antibodies can be produced according to per se known antibody or antiserum production methods.
- the isotype of the antibody is not particularly limited, but preferably IgG, IgM or IgA, particularly preferably IgG.
- the antibody is not particularly limited as long as it has at least a complementarity determining region (CDR) for specifically recognizing and binding a target antigen, and various forms similar to those described above can be used.
- CDR complementarity determining region
- the antibodies are preferably fully human antibodies, humanized antibodies, mouse-human chimeric antibodies, and the like. Is a fully human antibody.
- the substance that inhibits the interaction between Mincle and FcR ⁇ in the present invention is not limited to the antibody against Mincle and / or FcR ⁇ as described above, as long as it directly or indirectly inhibits the interaction between Mincle and FcR ⁇ .
- Other substances such as low molecular weight compounds may be used.
- Such a substance can be obtained, for example, by the screening method (II) or (III) of the present invention described later.
- the association between Mincle and FcR ⁇ involves the arginine residue (amino acid in the amino acid sequence represented by SEQ ID NO: 2) that is well conserved among mammalian species in the transmembrane domain of Mincle.
- the amino acid (number 41) is important.
- a substance that can specifically bind to the transmembrane region containing the arginine residue of Mincle can effectively inhibit the interaction between Mincle and FcR ⁇ . Since hydrophobicity is required when targeting a transmembrane region, the use of a fat-soluble low molecular weight compound is extremely advantageous.
- a substance that inhibits Mincle expression or Mincle's interaction with SAP130 or FcR ⁇ can block FcR ⁇ -dependent signal transduction and prevent an inflammatory response stimulated by non-homeostatic cell death. Therefore, a medicament containing a substance that inhibits Mincle expression or Mincle's interaction with SAP130 or FcR ⁇ can be used as various anti-inflammatory agents such as Crohn's disease, rheumatoid arthritis, Behcet's disease (eye symptoms).
- Ulcerative colitis Ulcerative colitis, ankylosing spondylitis, psoriasis (including psoriatic arthritis), HIV infection, multiple myeloma, congestive heart failure, GVHD, giant cell arteritis (GCA), polymyalgia rheumatica (PMR), pigmented purpuric lichenoid dermatitis, sarcoidosis, Wegener's granulomas, pyoderma, Behcet's disease, TNF receptor-related periodic syndrome (TRAPS), SAPHO syndrome, Takayasu disease, myositis, Still's disease, nodule Periarteritis (PN), relapsing polychondritis, scleroderma polymyositis, hemophagocytic syndrome, pemphigus, Kawasaki disease atopic dermatitis) That.
- GCA giant cell arteritis
- PMR polymyalgia rheumatica
- Drugs containing antibodies, low molecular weight compounds, etc. Drugs containing Mincle, SAP130 or FcR ⁇ antibodies, or low molecular weight compounds that inhibit Mincle expression or Mincle and SAP130 or FcR ⁇ interaction are low toxic. Or as a liquid or as a pharmaceutical composition in an appropriate dosage form orally to humans or other mammals (eg, mice, rats, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.) It can be administered parenterally (eg, intravascular administration, subcutaneous administration, etc.).
- the pharmaceutical composition used for administration may contain the above antibody or low molecular compound or a salt thereof and a pharmacologically acceptable carrier, diluent or excipient.
- Such pharmaceutical compositions are provided as dosage forms suitable for oral or parenteral administration.
- injections are dosage forms such as intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, infusions, and the like. May be included.
- Such an injection can be prepared according to a known method.
- a method for preparing an injection it can be prepared, for example, by dissolving, suspending or emulsifying the antibody or low molecular compound of the present invention or a salt thereof in a sterile aqueous or oily liquid usually used for injection.
- an aqueous solution for injection for example, an isotonic solution containing physiological saline, glucose and other adjuvants, and the like are used, and suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, Propylene glycol, polyethylene glycol), nonionic surfactants (eg polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct-of-hydrogenated-castor-oil)), etc. may be used in combination.
- alcohol eg, ethanol
- polyalcohol eg, Propylene glycol, polyethylene glycol
- nonionic surfactants eg polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct-of-hydrogenated-castor-oil)
- oily liquid for example, sesame oil, soybean oil and the like are used, and benzyl benzoate, benzyl alcohol and the like may be used in combination as a solubilizing agent
- compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like.
- Such a composition is produced by a known method and may contain a carrier, a diluent or an excipient usually used in the pharmaceutical field.
- a carrier and excipient for tablets for example, lactose, starch, sucrose, and magnesium stearate are used.
- the above parenteral or oral pharmaceutical composition is conveniently prepared in a dosage unit form suitable for the dose of the active ingredient.
- dosage form of such a dosage unit include tablets, pills, capsules, injections (ampoules), and suppositories.
- the antibody or low molecular weight compound is preferably contained in an amount of usually 5 to 500 mg per dosage unit form, particularly 5 to 100 mg for injections and 10 to 250 mg for other dosage forms.
- the dose of the above-mentioned pharmaceutical containing the above-mentioned antibody or low-molecular compound or a salt thereof varies depending on the administration subject, target disease, symptom, administration route, etc.
- the dose of antibody or low molecular weight compound is usually about 0.01 to 20 mg / kg body weight, preferably about 0.1 to 10 mg / kg body weight, more preferably about 0.1 to 5 mg / kg body weight per day. It is convenient to administer by intravenous injection about ⁇ 5 times, preferably about 1 to 3 times a day. In the case of other parenteral administration and oral administration, an equivalent amount can be administered. If symptoms are particularly severe, the dose may be increased according to the symptoms.
- compositions may contain other drugs as long as an undesirable interaction is not caused by blending with the above antibody or low molecular weight compound.
- drugs that can be used in combination with the above-mentioned antibodies and low molecular weight compounds include antibacterial drugs, antifungal drugs, nonsteroidal anti-inflammatory drugs, steroid drugs, anticoagulants, platelet aggregation inhibitors, thrombolytic drugs, and immunomodulators.
- Drugs containing nucleic acids such as antisense nucleic acid, siRNA, ribozyme, etc.
- Drugs containing antisense nucleic acid, siRNA, ribozyme and nucleic acid encoding them against Mincle mRNA are low toxic and can be used as solutions or as appropriate.
- the pharmaceutical composition of the dosage form is oral or parenteral (eg, intravascular) to a human or non-human mammal (eg, mouse, rat, rabbit, sheep, pig, cow, cat, dog, monkey, etc.) Administration, subcutaneous administration, etc.).
- nucleic acids When these nucleic acids are used as the above-mentioned anti-inflammatory agents, prophylactic / therapeutic agents for inflammatory diseases, etc., they can be formulated and administered according to methods known per se. That is, after inserting the nucleic acid of the present invention alone or in a functional manner into an appropriate expression vector for mammalian cells such as a retrovirus vector, lentivirus vector, adenovirus vector, adeno-associated virus vector, etc., according to conventional means. It can be formulated.
- the nucleic acid can be administered as it is or together with an auxiliary agent for promoting intake by a catheter such as a gene gun or a hydrogel catheter. Alternatively, it can be aerosolized and locally administered into the trachea as an inhalant.
- the nucleic acid may be formulated (injection) alone or with a carrier such as liposome and administered intravenously, subcutaneously, etc. .
- the nucleic acid of the present invention may be administered per se or as an appropriate pharmaceutical composition.
- the pharmaceutical composition used for administration may contain the nucleic acid of the present invention and a pharmacologically acceptable carrier, diluent or excipient.
- Such pharmaceutical compositions are provided as dosage forms suitable for oral or parenteral administration.
- injections for example, injections, suppositories and the like are used.
- Injections are dosage forms such as intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, infusions, and the like. May be included.
- Such an injection can be prepared according to a known method.
- Suppositories used for rectal administration may be prepared by mixing the nucleic acid with a normal suppository base.
- compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like.
- Such a composition is produced by a known method and may contain a carrier, a diluent or an excipient usually used in the pharmaceutical field.
- a carrier and excipient for tablets for example, lactose, starch, sucrose, and magnesium stearate are used.
- the above parenteral or oral pharmaceutical composition is conveniently prepared in a dosage unit form suitable for the dose of the active ingredient.
- dosage form of such a dosage unit include tablets, pills, capsules, injections (ampoules), and suppositories.
- the nucleic acid of the present invention is preferably contained, for example, usually 5 to 500 mg per dosage unit form, especially 5 to 100 mg for injections and 10 to 250 mg for other dosage forms.
- the dose of the above-mentioned medicament containing the nucleic acid of the present invention varies depending on the administration subject, target disease, symptom, administration route, etc.
- the amount of the nucleic acid of the invention is usually about 0.01 to 20 mg / kg body weight, preferably about 0.1 to 10 mg / kg body weight, more preferably about 0.1 to 5 mg / kg body weight, about 1 to 5 times a day, preferably It is convenient to administer by intravenous injection about 1 to 3 times a day. In the case of other parenteral administration and oral administration, an equivalent amount can be administered. If symptoms are particularly severe, the dose may be increased according to the symptoms.
- compositions may contain other drugs as long as an undesirable interaction is not caused by blending with the nucleic acid of the present invention.
- other drugs include those listed as drugs that can be used in combination with the above-described antibodies and low-molecular compounds.
- Mincle is activated by recognizing SAP130 released from dead cells, interacts with FcR ⁇ to induce production of inflammatory cytokines, and has an action of infiltrating neutrophils. Therefore, a substance that inhibits Mincle expression or Mincle's interaction with SAP130 or FcR ⁇ can be used as an anti-inflammatory agent in the prevention and treatment of various inflammatory diseases.
- substances that enhance Mincle expression or Mincle's interaction with SAP130 or FcR ⁇ may promote neutrophil infiltration into tissues that are damaged or infected with pathogens at an appropriate level and may promote tissue repair So it can be used as a therapeutic agent for tissue damage and infection. Therefore, the present invention also provides a method for screening a substance that modulates an inflammatory response by selecting a substance that modulates Mincle expression or the interaction between Mincle and SAP130 or FcR ⁇ .
- the present invention comprises contacting Mincle or a fragment containing its extracellular region with SAP130 in the presence and absence of a test substance, under both conditions
- the screening method of the substance which modulates an inflammatory reaction characterized by comparing the interaction degree of Mincle or its fragment in SAP130 with SAP130.
- the Mincle and SAP130 protein used in this screening method are as described in the explanation relating to the medicament of the present invention.
- the full length of Mincle may be used, or a fragment containing the extracellular region (in the case of the amino acid sequence represented by SEQ ID NO: 2, the region consisting of the amino acid sequence represented by amino acid numbers 45 to 219) is used. May be.
- the SAP130 protein includes a region involved in Mincle binding and Mincle activation, a fragment thereof can be used.
- Mincle and SAP130 are used to include the above functional fragments.
- Mincle and SAP130 protein can be obtained from the above-described cells or tissues producing the protein by appropriately combining known protein separation and purification techniques.
- these proteins are RNA, cDNA, cDNA prepared from a cell or tissue producing the protein using a probe or primer prepared based on the above-described nucleotide sequence information of the nucleic acid encoding the protein.
- a recombinant protein obtained by cloning from a library, etc., inserting into an appropriate expression vector and introducing it into a host cell, and culturing the transformed cell can also be obtained by recovery by a method known per se. .
- it can also be chemically synthesized by a known peptide synthesis method according to the amino acid sequence information of these proteins described above.
- this screening method comprises the following steps (a), (b) and (c): (a) contacting the test substance with Mincle and SAP130; (b) measuring the binding activity of Mincle contacted with the test substance with SAP130 and comparing the activity with the binding activity of SAP130 of the control Mincle not contacted with the test substance; (c) A step of selecting a test substance that modulates Mincle's binding activity to SAP130 based on the comparison result of (b).
- the test substance may be any known substance or new substance, for example, a nucleic acid, a carbohydrate, a lipid, a protein, a peptide, a low molecular weight organic compound, or a combinatorial chemistry technique.
- examples include compound libraries, random peptide libraries prepared by solid phase synthesis and phage display methods, and natural components derived from microorganisms, animals and plants, marine organisms, and the like.
- step (a) the test substance is brought into contact with Mincle and SAP130.
- the contact method is not particularly limited.
- the method of mixing Mincle and SAP130 at a predetermined concentration under physiological conditions of 25 to 37 ° C. and adding the test substance, SAP130 is fixed.
- Examples include a method of fixing to a phase and binding to Mincle in the presence of the test substance, or a method of adding the test substance and SAP130 to the culture medium of cells expressing Mincle.
- the concentration of the test substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of, for example, about 0.1 nM to about 100 nM. Examples of the incubation time include about 10 minutes to about 24 hours.
- the binding activity between Mincle and SAP130 can be measured by the method described in the following example.
- b-1) A method of immunoprecipitation using an anti-Mincle antibody or anti-SAP130 antibody, and performing Western blotting with an antibody not used in immunoprecipitation, and measuring the amount of binding between Mincle and SAP130.
- b-2) Either Mincle or SAP130 is expressed as a fusion protein with a label such as polyhistidine or GST, or biotinylated, polyhistidine binds to nickel, GST binds to glutathione, and biotin binds to avidin Therefore, a method of collecting the conjugate using them and measuring the amount of binding by Western blotting similar to b-1).
- b-4) A method of measuring the binding of fluorescently labeled Mincle to SAP130-expressing cells with a flow cytometer.
- step (b) the binding activity is compared based on, for example, the presence or absence of a significant difference in the amount of binding between Mincle and SAP130 in the presence or absence of the test substance.
- a test substance that reduces or increases the binding activity of Mincle with SAP130 is selected.
- the test substance with reduced binding activity is useful as a candidate for an anti-inflammatory substance, particularly a prophylactic / therapeutic agent for inflammatory diseases. They are also useful as immunomodulators and research reagents.
- a test substance having increased binding activity is useful as a candidate for a therapeutic agent for tissue damage or infection.
- (II) Screening method for substances regulating the interaction between Mincle and FcR ⁇ The present invention also expresses Mincle or its fragment containing extracellular and transmembrane regions and FcR ⁇ in the presence and absence of the test substance Provided is a screening method for a substance that modulates an inflammatory reaction, characterized by measuring and comparing the degree of interaction between Mincle or a fragment thereof and FcR ⁇ in a cell.
- the Mincle and FcR ⁇ protein used in this screening method are as described in the above explanation concerning the medicament of the present invention.
- Mincle may use its full length, or its extracellular region and transmembrane region (in the case of the amino acid sequence represented by SEQ ID NO: 2, the region consisting of the amino acid sequence represented by amino acid numbers 22 to 219)
- a containing fragment may be used.
- a fragment of FcR ⁇ protein can also be used as long as it contains a region involved in Mincle binding and intracellular signal transduction.
- Mincle and FcR ⁇ are used to include the above functional fragments.
- this screening method comprises the following steps (a), (b) and (c): (a) a step of expressing a test substance, Mincle and FcR ⁇ , and bringing a signal transmitted by their interaction (referred to as an “activation signal”) into contact with a measurable cell; (b) measuring the level of the activation signal in the cell contacted with the test substance and comparing the level with the level of the activation signal in a control cell not contacted with the test substance; (c) A step of selecting a test substance that regulates an inflammatory response based on the comparison result of (b).
- the cells that express Mincle and FcR ⁇ may be cells having endogenous Mincle and FcR ⁇ , or may be recombinant cells into which one or both of them are introduced.
- Examples of cells that endogenously express Mincle and FcR ⁇ include thymocytes, macrophages, dendritic cells, glial cells, Kupffer cells, and ganglion cells isolated from mammals.
- examples of host cells include H4IIE-C3 cells, HepG2 cells, 293T cells, HEK293 Examples thereof include animal cells such as cells, COS7 cells, 2B4T cells, CHO, MCF-7 cells, and H295R cells.
- the nucleic acid encoding Mincle and FcR ⁇ is isolated in the same manner as described above in the screening method (I), and inserted into an expression vector having a promoter that can function in the host cell.
- an expression vector having a promoter that can function in the host cell For example, calcium phosphate coprecipitation method, PEG method
- the vector can be prepared by introducing the vector into a host cell by electroporation, microinjection, lipofection, or the like.
- the contact between the test substance and the cell is, for example, a medium suitable for culturing the cell (for example, a minimum essential medium (MEM) containing about 5 to 20% fetal calf serum, Dulbecco's modified Eagle medium (DMEM), RPMI1640 Medium, 199 medium, F12 medium, etc.) and various buffers (eg, HEPES buffer, phosphate buffer, phosphate buffered saline, Tris-HCl buffer, borate buffer, acetate buffer, etc.) It can be carried out by adding a test substance and incubating the cells for a certain period of time.
- MEM minimum essential medium
- DMEM Dulbecco's modified Eagle medium
- RPMI1640 Medium 199 medium, F12 medium, etc.
- buffers eg, HEPES buffer, phosphate buffer, phosphate buffered saline, Tris-HCl buffer, borate buffer, acetate buffer, etc.
- the concentration of the test substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of about 0.1 nM to about 100 nM, for example.
- Examples of the incubation time include about 10 minutes to about 24 hours.
- step (b) the activation signal level is measured by measuring the response of the cell induced as a result of the signal.
- the activation signal can be measured by quantifying phosphorylation of a kinase located downstream of the signal transduction pathway via Mincle and FcR ⁇ , such as Syk, Erk, and CARD9. Phosphorylation of these molecules can be quantified by performing immunoassay such as Western blotting and ELISA on the cell lysate using an antibody specific for each phosphorylate. These phosphate specific antibodies are commercially available.
- the measurement of the activation signal is performed by measuring inflammatory cytokines / chemokines such as MIP-2, TNF ⁇ , IL-6, IL-8, IL-12, etc. produced by the activation of the above signal transduction pathway, for example,
- the antibody may be quantified by an immunoassay such as Western blotting or ELISA.
- the activation signal level is measured using the expression of a gene under the control of a promoter containing a base sequence capable of binding a transcription factor activated by Mincle and FcR ⁇ -mediated signal transduction as an index. be able to.
- transcription factors include NFAT and NF ⁇ B.
- Consensus cis sequences to which these transcription factors bind are well known in the art.
- An expression vector in which a DNA encoding a reporter protein eg, luciferase, GFP, peroxidase, alkaline phosphatase, etc.
- the expression of the reporter protein is induced, and by measuring this, the activation signal level is quantified. can do.
- step (b) the comparison of the activation signal level is performed based on the presence or absence of a significant difference in the activation signal level in the presence or absence of the test substance.
- the activation signal level in the control cells not contacted with the test substance is the expression level measured at the same time, even if the expression level was measured in advance compared to the measurement of the activation signal level in the cells contacted with the test substance.
- it is preferably the expression level measured simultaneously from the viewpoint of the accuracy and reproducibility of the experiment.
- step (c) a test substance that reduces or increases the activation signal level through the interaction between Mincle and FcR ⁇ is selected.
- a test substance having a reduced activation signal level is useful as a candidate for an anti-inflammatory substance, particularly a prophylactic / therapeutic agent for inflammatory diseases. They are also useful as immunomodulators and research reagents.
- a test substance having an increased activation signal level is useful as a candidate for a therapeutic agent for tissue damage or infection.
- (IV) Screening Method for Substances that Modulate Mincle Expression The present invention also measures and compares the amount of the protein or mRNA encoding the protein in Mincle-producing cells in the presence and absence of the test substance.
- a screening method for a substance that modulates an inflammatory response is provided.
- the screening method for a substance that regulates the expression of Mincle of the present invention includes the following steps (a), (b) and (c): (A) contacting the test substance with a cell capable of measuring Mincle expression; (B) measuring the expression level of Mincle in a cell contacted with a test substance, and comparing the expression level with the expression level of Mincle in a control cell not contacted with the test substance; (C) A step of selecting a test substance that decreases the expression level of Mincle based on the comparison result of (b).
- the test substance is as described above.
- the cells capable of measuring Mincle expression include all cultured cells that express Mincle regardless of whether they are endogenous or exogenous, or cells containing a reporter gene under the control of the Mincle gene's endogenous promoter. Whether or not these genes are expressed in cultured cells can be easily confirmed by detecting the expression of these genes by a known Northern blot method or RT-PCR method.
- cells capable of measuring Mincle expression can be provided in the form of a tissue or organ producing Mincle isolated from a non-human mammal, or a non-human mammal individual. Alternatively, it may be a cell, tissue, organ or individual of a transgenic animal into which a reporter gene under the control of the Mincle gene's endogenous promoter is introduced.
- the contact between the test substance and the cells can be performed as described above.
- the contact between the test substance and the cells is performed by administering the test substance to the animal.
- the administration route is not particularly limited, and examples thereof include intravenous administration, intraarterial administration, subcutaneous administration, intradermal administration, intraperitoneal administration, oral administration, intratracheal administration, and rectal administration.
- the dose is not particularly limited. For example, a dose of about 0.5 to 20 mg / kg can be administered 1 to 5 times a day, preferably 1 to 3 times a day for 1 to 14 days.
- step (b) the expression level of Mincle is measured for mRNA or protein.
- the expression level of mRNA is measured, for example, by preparing total RNA from cells and performing RT-PCR, Northern blotting, or the like.
- the amount of protein expression can be measured, for example, by preparing an extract from cells and immunologically.
- Western blotting, radioisotope immunoassay (RIA method), ELISA, fluorescent antibody method and the like can be used.
- a cell containing a reporter gene linked downstream of the Mincle gene promoter for example, luciferase, GFP
- the expression level is measured based on the signal intensity of the reporter protein.
- the presence of SAP130 induces Mincle gene expression. Therefore, in the step (a), by contacting the test substance with cells in the presence of SAP130, a substance capable of regulating the expression of Mincle gene induced by the stimulation of SAP130 can be screened.
- a method of coexisting SAP130 in the step (a) when cells are provided in the form of cultured cells or the like, addition of SAP130 to the medium can be mentioned, but non-constant cell death is caused by irradiation or the like. It can also be carried out by partially inducing cell death by adding an induced cell or irradiating the cell itself capable of measuring Mincle expression with an appropriate amount of radiation.
- SAP130 can be provided by partially inducing cell death, such as by irradiating the animal.
- the screening method of the present invention is to prepare primers or probes by a known method based on the Mincle gene sequence, and to perform Northern blotting, RT-PCR, DNA chip It can be carried out by using as an indicator that the amount of RNA or transcript thereof bound to the disease marker is increased by an analysis method, an in situ hybridization analysis method, or the like.
- the presence or absence of the Mincle gene in RNA and its expression level can be detected and measured by using the probe of the present invention.
- the probe complementary strand
- RI radioisotope
- a fluorescent substance a marker derived from the cells transferred to a nylon membrane or the like according to a conventional method
- the formed double strand of the probe (DNA) and RNA is used to detect a signal derived from a marker (RI or fluorescent substance) of a disease marker as a radiation detector (BAS-1800II, manufactured by Fuji Film) or a fluorescence detector.
- BAS-1800II manufactured by Fuji Film
- fluorescence detector a fluorescence detector
- the probe (probe DNA) is labeled according to the protocol and hybridized with RNA derived from the subject's biological tissue
- a method of detecting and measuring a signal derived from the label with a multi-bioimager STORM860 can also be used.
- the expression of the Mincle gene in RNA can be achieved by using a polynucleotide having at least 15 consecutive nucleotides in the Mincle gene base sequence and / or a polynucleotide complementary thereto as a primer. Presence / absence and expression level can be detected and measured.
- cDNA is prepared from RNA derived from the cells according to a conventional method, and this is used as a template to bind the prepared pair of primers (the above cDNA (-strand) so that the target Mincle gene region can be amplified.
- a reverse strand that binds to the positive strand and a PCR method according to a conventional method, and a method for detecting the resulting amplified double-stranded DNA can be exemplified.
- the detection of the amplified double-stranded DNA was performed by a method for detecting the labeled double-stranded DNA produced by performing the PCR using a primer previously labeled with RI or a fluorescent substance.
- a method can be used in which double-stranded DNA is transferred to a nylon membrane or the like according to a conventional method, and a labeled disease marker is used as a probe to hybridize with the probe to detect it.
- the produced labeled double-stranded DNA product can be measured with an Agilent 2100 Bioanalyzer (manufactured by Yokogawa Analytical Systems). Also, prepare an RT-PCR reaction solution according to the protocol using SYBR Green RT-PCR Reagents (Applied Biosystems), and react with ABI PRISM 7700 Sequence Detection System (Applied Biosystems) to detect the reaction product. You can also.
- a DNA chip with a Mincle gene partial sequence attached as a DNA probe (single-stranded or double-stranded). For example, prepare it from the cell-derived RNA using a conventional method. There can be mentioned a method in which a double strand of DNA and cRNA formed by hybridization with cRNA labeled with biotin is detected with fluorescently labeled avidin.
- the above-mentioned cells are fixed and embedded, and a section is prepared.
- a specific antisense probe or sense probe of the Mincle gene is prepared.
- the probe is labeled with an RI label or a non-RI label (eg, DIG label).
- the section is deparaffinized (in the case of a paraffin section) and pretreated, and then fixed with ethanol or the like. After pre-hybridizing the fixed section and hybridizing with the probe, washing and RNase treatment are performed, and a detection method according to the label (for example, development for RI labeling, immunological detection for non-RI labeling) The presence or absence of Mincle gene expression in living tissue and its expression level can be detected and measured.
- the screening method of the present invention uses an anti-Mincle antibody, Western blotting, radioisotope immunoassay (RIA method), ELISA method, fluorescent antibody method, This can be carried out by using as an index the increase in the amount of protein bound to the antibody by immunocytostaining or the like.
- an anti-Mincle antibody As the primary antibody, then use a secondary antibody labeled with a radioisotope such as 125I, a fluorescent substance, or an enzyme such as horseradish peroxidase (HRP) as the secondary antibody.
- a radioisotope such as 125I, a fluorescent substance, or an enzyme such as horseradish peroxidase (HRP)
- HRP horseradish peroxidase
- an antibody an antibody that binds to the primary antibody
- the signal derived from the radioisotope and fluorescent substance of the obtained labeled compound is detected with a radiation measuring instrument (BAS-1800II: manufactured by Fuji Film), a fluorescence detector, etc. This can be done by detecting and measuring.
- Mincle positive cells can be measured using an enzyme-labeled antibody and its chromogenic substrate in accordance with the method described in Example 4 described later.
- step (b) the expression level is compared based on the presence or absence of a significant difference in the expression level of Mincle in the presence or absence of the test substance.
- the expression level of Mincle in the control cells not contacted with the test substance is the expression level measured at the same time, even if the expression level was measured in advance compared to the measurement level of Mincle expression in the cells contacted with the test substance.
- it is preferably the expression level measured simultaneously from the viewpoint of the accuracy and reproducibility of the experiment.
- step (c) a test substance that reduces or increases Mincle expression is selected.
- a test substance with reduced expression of Mincle is useful as a candidate for an anti-inflammatory substance, particularly a prophylactic / therapeutic agent for inflammatory diseases. They are also useful as immunomodulators and research reagents.
- a test substance with increased expression of Mincle is useful as a candidate for a therapeutic agent for tissue damage or infection.
- a medicament containing a substance selected by the screening methods (I) to (IV) above has low toxicity and is used as a liquid or as a pharmaceutical composition in an appropriate dosage form as a human or non-human mammal (eg, Mice, rats, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.) orally or parenterally (eg, intravascular administration, subcutaneous administration, etc.).
- the pharmaceutical composition used for administration may comprise a selected substance and a pharmacologically acceptable carrier, diluent or excipient.
- Such pharmaceutical compositions are provided as dosage forms suitable for oral or parenteral administration.
- the pharmacologically acceptable carrier, diluent or excipient those described above can be used.
- the dose of the above medicament varies depending on the administration subject, target disease, symptom, administration route, etc., for example, when used for the treatment and prevention of adult rheumatoid arthritis, the active ingredient is taken as a single dose, Usually about 0.01 to 20 mg / kg body weight, preferably about 0.1 to 10 mg / kg body weight, more preferably about 0.1 to 5 mg / kg body weight, about 1 to 5 times a day, preferably about 1 to 3 times a day, vein Conveniently administered by injection. In the case of other parenteral administration and oral administration, an equivalent amount can be administered. If symptoms are particularly severe, the dose may be increased according to the symptoms.
- the present invention also provides a method for detecting non-homeostatic cell death, which comprises measuring the amount of SAP130 in a sample collected from a test animal.
- test animals include humans and other mammals, preferably humans, mice, rats, rabbits, dogs, monkeys and the like that are widely used as experimental animals.
- Samples to be measured include blood, plasma, serum, lymph, saliva, mucous membrane, urine, tears, semen, and joint fluid.
- the amount of SAP130 in a sample can be measured using, for example, an anti-SAP130 antibody, Mincle or a fragment containing a region involved in binding with SAP130.
- an anti-SAP130 antibody, Mincle or a fragment containing a region involved in binding with SAP130 For example, after adding a sample solution to a reaction vessel (such as a microtiter plate) in which the first anti-SAP130 antibody or Mincle or a fragment thereof is immobilized, and incubating for a certain time, the liquid phase is removed, SAP can be quantified by adding a labeled second anti-SAP antibody or anti-Mincle antibody and measuring the amount of label bound to the solid phase.
- the labeling substance examples include radioisotopes (eg, [ 125 I], [ 131 I], [ 3 H], [ 14 C], etc.), enzymes (eg, ⁇ -galactosidase, ⁇ -glucosidase, alkaline phosphatase, Peroxidase, malate dehydrogenase), fluorescent substances (for example, fluorescamine, fluorescein isothiocyanate, etc.), luminescent substances (for example, luminol, luminol derivatives, luciferin, lucigenin, etc.) are used. It will be apparent to those skilled in the art that in addition to the above method, the amount of SAP130 in the sample can be measured using other immunological techniques, surface plasmon resonance, or the like.
- radioisotopes eg, [ 125 I], [ 131 I], [ 3 H], [ 14 C], etc.
- enzymes eg, ⁇ -galactosidase, ⁇ -glucosidase
- mice C57BL / 6 (B6) mice were purchased from Clea Japan.
- B6 background FcR ⁇ ⁇ / ⁇ mice were established as described in Park, SY et al., J Clin Invest 102, 1229-38 (1998).
- CARD9 ⁇ / ⁇ mice were established as described in Hara, H. et al., Nat Immunol 8, 619-29 (2007) and backcrossed 6 times with B6.
- B6 background MyD88 -/- mice were from S. Akira (Osaka University).
- Fc ⁇ RI ⁇ / ⁇ and Fc ⁇ RIII ⁇ / ⁇ mice were from J. S. Verbeek (Leiden University). All mice were maintained in a breeding rack with a laminar flow of air filters and had free access to standard food and water. All animal experiments were conducted according to our institutional guidelines.
- Mincle cDNA was cloned by PCR and inserted into pMX-IRES-hCD8 vectors 50.
- Mincle-Flag was prepared using the same primers as previously described (Matsumoto, M. et al., J Immunol 163, 5039-48 (1999)).
- Ig-Mincle fusion protein the extracellular domain of mouse Mincle (amino acids 46-214) was fused to hIgG Fc by PCR.
- SAP130 cDNA was cloned by PCR and inserted into pcDNA3.1-V5-His-TOPO (Invitrogen).
- Antibody A rabbit anti-Mincle polyclonal antibody was prepared against a peptide (amino acids 1-16) corresponding to the cytoplasmic region of mouse Mincle.
- Anti-phospho-Erk Ab is Promega
- Anti-phospho-Syk is Cell Signaling Technology
- Anti-human IgG-HRP and Protein G Sepharose are Amersham Biosciences (Piscataway, NJ)
- Anti-rat IgG-HRP is Zymed
- Anti-rat IgG-PE is Jackson Immunoresearch
- anti-Histone-H1 and anti-SAP145 were purchased from Santa Cruz
- anti-SAP49 from Abcam anti-SAP130 from Novus Biologicals
- SAP155 from MBL
- anti-DDB1 from BD Biosciences
- anti-Flag from Sigma.
- Ig-Mincle Mincle's extracellular domain (amino acids 46-214) was fused to the C-terminus of hIgG Fc region lacking a stop codon by PCR and inserted into the XhoI / NotI fragment of pME18S-SLAMsig-hIgG Fc.
- 293T cells were transiently transfected with pME18S-SLAMsig-hIgG Fc (Ig) or pME18S-SLAMsig-hIgG Fc-Mincle (Ig-Mincle). The cells were cultured in a protein-free medium (PFMH-II).
- the filtered supernatant was applied to a Protein A-Sepharose column, and the bound fraction was eluted with 50 mM diethylamine and immediately neutralized with Tris-HCl (pH 7.5). The main fraction was dialyzed against PBS and used as a purified Ig fusion solution. Protein molecular weight and purity were estimated by silver staining and Western blot using anti-hIgG-HRP (Pierce). Leucine-zipper Fas-ligand (FasL) was provided by S. Nagata (Kyoto University).
- Mincle sequences were obtained from the NCBI server. Mincle partial sequence ranging from 79 to 214 residues was extracted and its three-dimensional structure was predicted using the general method of homology modeling.
- the crystal structure of DC-SIGN (PDB-entry: 1nfd) was taken as a template for generating a homology model from Protein Data Bank (PDB).
- the partial sequence of Mincle was aligned with the template protein using NW alignment. In order to obtain an appropriate alignment, the gaps and Cys residues in Mincle were manually replaced with the corresponding Cys residue positions in the template. Appropriate alignment was achieved and the main chain atoms in the target protein were assigned to the coordinates of the corresponding residues in the DC-SIGN template protein.
- Insertions and deletions in the loop region were modeled by searching for suitable structures from a fragment database made from fragments of proteins with known structures.
- a side chain was constructed in the backbone of the Mincle model using the Metropolis Monte Carlo method.
- 2000 steps of optimization were performed by the steepest descent method using AMBER8 of the molecular dynamics package.
- FIG. 1d was prepared with ViewerLite® (Accelrys).
- RNA expression was quantified by real-time PCR by using gene-specific primers, and values were normalized by ⁇ -actin expression.
- the gene-specific primer sequences are as follows: ⁇ -actin, 5'-TGGAATCCTGTGGCATCCATGAAAC-3 '(forward) 5'-TAAAACGCAGCTCAGTAACAGTCCG-3 '(reverse); IL-6, 5'-TTCCATCCAGTTGCCTTCTTGG-3 '(forward) 5'-CTTCATGTACTCCAGGTAG-3 '(reverse); TLR2, 5'-CAGCTTAAAGGGCGGGTCAGA-3 '(forward) 5'-TGGAGACGCCAGCTCTGGCTC-3 '(reverse); Mincle, 5'-GCTCCAGCAGGGAACAATAG-3 '(forward) 5'-GCCCTTTGATGGAATTCAGA-3 '(reverse); and FcR ⁇ , 5'-CCTTCCCTTCCCTCTACACC-3 '(forward) 5'-AAGGTAAGGCAGGGTGGTCT-3 '(reverse).
- Anti-Mincle monoclonal antibodies were established by immunizing Wistar rats with basophilic leukemia (RBL-2H3) cells expressing mouse Mincle. Cloned hybridoma supernatants were screened by staining 2B4 cells expressing Mincle-IRES-GFP. The characteristics of three independent clones 1B6 (IgG1, ⁇ ), 4A9 (IgG1, ⁇ ) and 6E2 (IgG2c, ⁇ ) were examined (FIG. 1) and used in this study. The level of endotoxin in each monoclonal antibody was 1 EU / ml (Limulus Color KY Test, Wako) or less. The biotinylation of the monoclonal antibody was performed using EZ-link biotinylation kit (Pearce) (FIG. 1).
- Epitope mapping of anti-Mincle monoclonal antibody was performed by peptide-based ELISA. 79 biotinylated peptides encapsulating Mincle's extracellular domain (length 13 a.a, overlapping 11 a.a.) were synthesized by JPT Peptide Technologies. Each peptide was bound to a multiwell plate (PerkinElmer) coated with streptavidin at 0.5 nM. After blocking with 1 ⁇ g / ml BSA, 10 ⁇ g / ml rat IgG and anti-Mincle monoclonal antibody were added. After washing, 1 ⁇ g / ml anti-rat IgG-HRP was added and color development was performed using TMBZ peroxidase substrate (SUMILON) (FIG. 1).
- SUMILON TMBZ peroxidase substrate
- Example 2 An alignment of mouse, rat and human Mincle amino acid sequences revealed that there is a conserved arginine residue in the transmembrane domain ( Figure 2a). As described for other immune receptors, the presence of positively charged residues within this transmembrane moiety may allow Mincle to interact with adapter molecules (FcR ⁇ , DAP10, DAP12 and CD3 ⁇ ) containing ITAM. It is suggested. In order to verify whether Mincle can bind to any of these subunits, Mincle was transfected into 293T with these adapters.
- adapter molecules FcR ⁇ , DAP10, DAP12 and CD3 ⁇
- Mincle has a potential serine / threonine phosphorylation site in its cytoplasmic region, but Mincle's deletion mutant lacking the C-terminal tail (Mincle ⁇ 2-18 ) does not diminish signaling ability in similar systems (Data omitted).
- Example 3 Next, to verify whether endogenous Mincle can convert the activation signal, thioglycolic acid-induced peritoneal macrophages were stimulated with anti-Mincle antibodies. Immobilized anti-Mincle induced production of TNF ⁇ , MIP-2 (CXCL2) Figure 3a), KC (CXCL1) and IL-6 (data not shown) but not with control IgG. Mincle-induced inflammatory cytokine production was not FcR ⁇ ⁇ / ⁇ cells, but FcR ⁇ -independent LPS stimulation induced comparable amounts of cytokines (FIG. 3b). MyD88, an important adapter for TLR signaling, was not essential for Mincle-mediated cytokine production (FIG. 3b). Therefore, Mincle converts the activation signal in an FcR ⁇ -dependent manner and transmits it to the macrophages.
- Mincle cross-linking induced phosphorylation of cellular proteins including kinases Syk and Erk in peritoneal macrophages (FIG. 3c).
- Syk directly bound to phosphorylated ITAM and induced phosphorylation of multiple downstream substrates. Therefore, the induction of global tyrosine phosphorylation by anti-Mincle monoclonal antibody was markedly suppressed in FcR ⁇ -/- macrophages (Fig. 3d, right lane), which is due to Mincle inducing FcR ⁇ -Syk to induce downstream signals. Suggest to use cascade.
- CARD9 has been shown to be essential for linking Syk to inflammatory responses.
- BMM ⁇ bone marrow-derived macrophages
- Example 5 Next, we tried to discover Mincle's physiological ligands. Secretion of inflammatory cytokines and chemokines by myeloid cells is a potential indicator that can be used for screening ligand candidates. However, such cytokines and chemokines are also produced in large quantities upon TLR stimulation. Therefore, to distinguish the putative Mincle ligand from the potentially contaminating TLR ligand, we used a non-myeloid T cell hybridoma as the host cell and the NFAT-GFP reporter specific for the ITAM-mediated signal Used as detection means.
- Mincle contains an EPN motif, a well-studied mannose-binding motif, in its C-type lectin domain.
- EPN motif a well-studied mannose-binding motif
- QPD motif a well-studied mannose-binding motif
- the QPD motif is known to bind selectively to galactose.
- Mutant Mincle with E169Q / N171D (MincleEPN-> QPD) still transmitted the activation signal in response to dead cells as well as the wild type. This suggests that Mincle recognizes its ligands independently of hydrocarbons (Fig. 5e).
- C-type lectins recognize non-hydrocarbon ligands as well as hydrocarbon ligands.
- Mincle mutants lacking the VEGQW sequence of the epitope recognized by the potent inhibitory monoclonal antibody 1B6 (FIG. 1) abolish NFAT activation (FIG. 5e). This suggests that these residues are important for the recognition of dead cell derived Mincle ligands.
- Mincle ligand from dead cells, we constructed a soluble Mincle protein. Since Mincle is a type II membrane protein, Mincle's extracellular domain was fused to human immunoglobulin GFc domain (Ig-Mincle) (FIG. 6a). We first examined whether Ig-Mincle specifically recognizes dead cells. Ig-Mincle selectively bound AnnexinV + PI + thymus (FIG. 6b) and 2B4 dead cells (data not shown), but no control Ig. Thus, it appears that dead cells express Mincle-binding protein.
- Ig-Mincle immunoglobulin GFc domain
- Ig-Mincle binds to dead cells without Ca 2+ even though Ca 2+ is known to be essential for the recognition of hydrocarbon ligands for lectins. Therefore, to search for Mincle ligand candidates, we used Ig-Mincle to search for Mincle-binding proteins from dead cell lysates in the absence of Ca 2+ .
- Ig-Mincle search for Mincle-binding proteins from dead cell lysates in the absence of Ca 2+ .
- p130 130 kD protein that specifically bound to Ig-Mincle but not to control Ig in a reproducible manner
- Fig. 6c we purified Mincle-binding protein by a series of column purifications using dead cell lysates.
- spliceosome-binding protein 130 also known as SAP130, Sf3b3
- snRNP small nuclear ribonucleoprotein
- SAP130 is remarkably homologous to damaged DNA binding protein 1 (DDB1), which binds to UV damaged DNA.
- DDB1 DNA binding protein 1
- immunoblotting with anti-SAP130 showed that Ig-Mincle selectively binds to SAP130 and not DDB1 (FIG. 6e).
- the nuclear protein high mobility group box 1 (HMGB1) secreted from dead cells and reported to act as a signal to alert the immune system of excessive or non-homeostatic cell death, is another candidate for Mincle ligand.
- HMGB1 did not interact with either Ig-Mincle (FIG. 6e, f) or activated Mincle-expressing NFAT-GFP (data not shown).
- SAP130 is a normal living cell and is localized in the nucleus, the migration of SAP130 to the external environment upon cell death can be a warning signal for non-homeostatic cell death. Indeed, it is known that Sm protein, another component of snRNPs, is transferred from late apoptotic or necrotic cells to the supernatant. Consistent with this idea, a significant amount of SAP130 was released from dead cells when compared to another typical nuclear protein, histone H1 (FIG. 6g). Release of SAP130 was also evident during Fas-ligand (Fas-L) -induced cell death and was closely correlated with the appearance of propidium iodide (PI) + late apoptotic / necrotic cells (FIG. 6h).
- Fas-ligand Fas-ligand
- PI propidium iodide
- Example 7 2B4T cell hybridomas were cultured for 4 days to generate dead cells. 1 ⁇ 10 8 cells in 1% NP-40 lysis buffer (1% NP-40, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 10 ⁇ g / ml aprotinin, 12.5 ⁇ g / ml chymostatin, 50 ⁇ g / ml leupeptin, 25 ⁇ g / ml pepstatin A, 1 mM phenylmethylsulfonyl fluoride) was dissolved.
- 1% NP-40 lysis buffer 1% NP-40, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 10 ⁇ g / ml aprotinin, 12.5 ⁇ g / ml chymostatin, 50 ⁇ g / ml leupeptin, 25 ⁇ g / ml pepstatin A, 1 mM
- Ig and Ig-Mincle proteins were covalently bound to Protein G Sepharose 4 Fast Flow (Amersham Bioscience) using dimethyl pimelimidate (Pierce) and ethanolamine. Cell lysates were eluted twice through Protein G Sepharose and then three times through Ig-coupled Protein G Sepharose. The flow-through fraction was applied to an Ig-Mincle-bound Protein G Sepharose column, and the column was washed with a lysis buffer. The bound fraction was eluted by boiling with sample buffer, separated by SDS-PAGE, subsequently transferred to PVDF and stained with Colloidal Gold Total Protein Stain (Bio-Rad). A band corresponding to p130 was cut out and analyzed by MALDI-TOF / MS in Protein Research Network, Inc. (FIG. 7).
- V130-tagged SAP130 was expressed in 293T cells, purified from cell lysate using anti-V5 agarose, and subsequently eluted with V5 peptide.
- SAP130 cDNA was inserted into pLP-BacPAK9-6xHN baculovirus vector (Clontech) and infected with recombinant baculovirus in Sf9 cells. The cell supernatant was purified with Q-Sepharose Fast Flow (GE Healthcare) and TALON metal affinity resins (Clontech) (Fig. 7).
- Example 8 Next, we verified whether purified SAP130 could activate Mincle-expressing cells.
- V5-tagged SAP130 was expressed in 293T cells and eluted from the cell lysate by elution with V5 peptide using anti-V5-agarose.
- peritoneal macrophages were stimulated with SAP130-V5 on anti-V5 coated on the plate, a significant amount of MIP-2 was secreted into the supernatant (FIG. 8a). Similar stimulation also induced IL-2 production from T cell hybridomas expressing Mincle and FcR ⁇ (FIG. 8b). This greatly reduced the possibility that the purified protein activity was due to contaminated endotoxin.
- SAP-130-V5 has no effect on parent cells that do not express Mincle (FIG. 8b). Furthermore, SAP130-V5-induced IL-2 production by Mincle-expressing cells was almost completely inhibited by soluble anti-Mincle monoclonal antibody (FIG. 8b). These results suggest that SAP130 can act as an endogenous ligand for Mincle.
- SAP130 is a Mincle functional ligand. Since SAP130 is an endogenous nuclear protein, recognition of SAP130 by Mincle can be a signal for the occurrence of excessive cell death.
- Example 9 Finally, we examined the physiological function of Mincle in vivo. Several reports have demonstrated that excessive or non-homeostatic cell death induces transient infiltration of inflammatory cells in the absence of infection. A model system for studying this phenomenon involves whole body irradiation of mice, which induces massive death of CD4 + CD8 + double positive (DP) thymocytes in the cortical region ( Figures 9a, b). ) And consequently induces transient infiltration of neutrophils into the thymus (FIG. 9b, right panel).
- DP double positive
- Mincle mRNA increased rapidly after whole-body irradiation (Fig. 9c).
- the increase in Mincle occurred prior to the induction of TLR2 and FcR ⁇ , and this increase was attributed to Mincle's transcriptional activation because it showed infiltration of inflammatory cells within the thymus (FIG. 9c).
- Mincle induces neutrophil infiltration by recognizing dead cells.
- Administration of anti-Mincle monoclonal antibody for blocking dramatically suppressed neutrophil infiltration into the thymus after irradiation (Fig. 9d, e), while the frequency of thymocyte death itself was altered by monoclonal antibody treatment did not (data omitted).
- MIP-2 produced by thymic macrophages has been reported to be important for neutrophil recruitment.
- Anti-Mincle treatment inhibited MIP-2 production by thymic macrophages (FIG. 9f). This suggested that this monoclonal antibody blocked the Mincle-ligand interaction in order to induce inflammatory cytokine / chemokine from macrophages.
- C-type lectin receptors are important immunoreceptors because of the recognition of various self and non-self ligands.
- pathogen components recognized by C-type lectins have been well written, self-ligands are not well understood. Roughly speaking, they seem to be molecules related to tissue damage.
- the endocytic receptors MBL, Lox-1 and MGL-1 can recognize ligands from dead cells and participate in their cleanup.
- Mincle is not an endocytic receptor because anti-Mincle monoclonal antibodies did not block phagocytosis of thymic dead cells (FIG. 12). None of the lectin receptors can mediate signal transduction through ITAM, although none have been found to recognize damaged self. Mincle is therefore the first ITAM-coupled receptor that directly recognizes dead cells.
- SAP130 Mincle's ligand. Within the U2 snRNP complex, SAP130 interacts with SAP145, SAP155 and SAP49 to form spliceosomes (FIG. 13a). Thus, SAP155, SAP145 and SAP49 also co-precipitate with Ig-Mincle, but not as efficiently as SAP130 (FIG. 13b). Although our data using purified SAP130 suggest that it activates Mincle-expressing cells on its own, it is unclear at this time whether complex formation enhances Mincle's reactivity.
- the screening method of the present invention makes it possible to search for a novel anti-inflammatory agent that can fundamentally inhibit the activation signal of the inflammatory reaction.
- the anti-inflammatory agent of this invention obtained by this can be provided for the treatment of an inflammatory disease.
- the diagnosis method of the present invention can diagnose the presence or absence of cell death in a tissue that induces an inflammatory reaction.
- an agonist of an inflammatory response can be searched for, and it can be provided as a therapeutic agent that promotes infiltration of neutrophils into tissue damaged or infected with a pathogen at an appropriate level, and consequently promotes tissue repair.
- the present invention is based on Japanese Patent Application No. 2008-186570 filed on July 17, 2008, the entire contents of which are included in the present specification.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Rehabilitation Therapy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
また、本発明の別の目的は、ミンクルの生理的リガンドを同定し、その生理学的機能を解明することである。
本発明者らは、これらの知見に基づいてさらに研究を重ねた結果、本発明を完成するに至った。
[1]ミンクルの発現またはミンクルとSAP130もしくはFcRγとの相互作用を阻害する物質を含有してなる抗炎症剤。
[2]ミンクルとSAP130との相互作用を阻害する物質がミンクルに対する抗体である、[1]に記載の剤。
[3]抗体が、配列番号:2で表されるヒトミンクルのアミノ酸配列中アミノ酸番号146~150で示されるアミノ酸配列もしくは他の哺乳動物のオルソログにおける対応するアミノ酸配列を認識する、[2]に記載の剤。
[4]ミンクルとSAP130との相互作用を阻害する物質が、配列番号:2で表されるヒトミンクルのアミノ酸配列中アミノ酸番号146~150で示されるアミノ酸配列もしくは他の哺乳動物のオルソログにおける対応するアミノ酸配列を含むペプチドである、[1]に記載の剤。
[5]ミンクルとSAP130との相互作用を阻害する物質が、SAP130に対する抗体である、[1]に記載の剤。
[6]ミンクルの発現を阻害する物質が、ミンクル遺伝子に対するアンチセンス核酸、リボザイムまたはsiRNAである、[1]に記載の剤。
[7]ミンクルとFcRγとの相互作用を阻害する物質が、ミンクルおよび/またはFcRγに対する抗体である、[1]に記載の剤。
[8]ミンクルとFcRγとの相互作用を阻害する物質が、ミンクルの膜貫通ドメイン中の保存されたアルギニン残基を含む部位に結合する、[1]に記載の剤。
[9]炎症性疾患の予防および/または治療のための、[1]~[8]のいずれかに記載の剤。
[10]ミンクルもしくはその細胞外領域を含む断片とSAP130とを、被験物質の存在下および非存在下で接触させ、両条件下におけるミンクルもしくはその断片とSAP130との相互作用の程度を比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法。
[11]被験物質の存在下および非存在下で、ミンクルもしくはその細胞外および膜貫通領域を含む断片とFcRγとを発現する細胞における、ミンクルもしくはその断片とFcRγとの相互作用の程度を測定・比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法。
[12]ミンクルおよびFcRγを介するシグナル伝達経路の活性化を指標として、ミンクルもしくはその断片とFcRγとの相互作用の程度を比較する、[11]に記載の方法。
[13]ミンクルおよびFcRγを介するシグナル伝達により活性化される転写因子が結合し得る塩基配列を含むプロモーターの制御下にある遺伝子の発現を指標とする、[12]に記載の方法。
[14]さらにSAP130を共存させることを特徴とする、[11]~[13]のいずれかに記載の方法。
[15]被験物質の存在下および非存在下で、ミンクルを産生する細胞における該蛋白質またはそれをコードするmRNAの量を測定・比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法。
[16]さらにSAP130を共存させることを特徴とする、[15]に記載の方法。
[17]抗炎症作用を有する物質の選択のための、[10]~[16]のいずれかに記載の方法。
[18]被験動物より採取した試料中のSAP130量を測定することを特徴とする、非恒常性細胞死の検出方法。
これらの蛋白質は、ヒトや他の温血動物(例えば、モルモット、ラット、マウス、ニワトリ、ウサギ、イヌ、ブタ、ヒツジ、ウシ、サルなど)の細胞[例えば、肝細胞、脾細胞、神経細胞、グリア細胞、膵臓β細胞、骨髄細胞、メサンギウム細胞、ランゲルハンス細胞、表皮細胞、上皮細胞、杯細胞、内皮細胞、平滑筋細胞、線維芽細胞、線維細胞、筋細胞、脂肪細胞、免疫細胞(例、マクロファージ、T細胞、B細胞、ナチュラルキラー細胞、肥満細胞、好中球、好塩基球、好酸球、単球)、巨核球、滑膜細胞、軟骨細胞、骨細胞、骨芽細胞、破骨細胞、乳腺細胞もしくは間質細胞、またはこれら細胞の前駆細胞、幹細胞もしくは癌細胞など]あるいはそれらの細胞が存在するあらゆる組織[例えば、脳、脳の各部位(例、嗅球、扁桃核、大脳基底球、海馬、視床、視床下部、大脳皮質、延髄、小脳)、脊髄、下垂体、胃、膵臓、腎臓、肝臓、生殖腺、甲状腺、胆のう、骨髄、副腎、皮膚、筋肉(例、平滑筋、骨格筋)、肺、消化管(例、大腸、小腸)、血管、心臓、胸腺、脾臓、顎下腺、末梢血、前立腺、睾丸、卵巣、胎盤、子宮、骨、関節、脂肪組織(例、白色脂肪組織、褐色脂肪組織)など]等から、自体公知の蛋白質分離精製技術により単離・精製されるものであってよい。
ここで「活性」とは、ミンクルの場合、SAP130と相互作用して、FcRγを介して炎症性サイトカイン等の産生を誘導する活性、好中球を輸送させる活性をいい、SAP130の場合、ミンクルと相互作用してミンクルを活性化する能力をいい、FcRγの場合、ミンクルと共役して炎症性サイトカイン等の産生を誘導する活性、好中球を輸送させる活性をいう。また、「実質的に同質」とは、例えば生理学的に、あるいは薬理学的にみて、その性質が定性的に同一であることを意味する。したがって、該活性は同等であることが好ましいが、これらの活性の程度(例、約0.01~約100倍、好ましくは約0.1~約10倍、より好ましくは0.5~2倍)や、蛋白質の分子量などの量的要素は異なっていてもよい。
ミンクルとSAP130およびミンクルとFcRγとの相互作用、好中球の輸送活性は、自体公知の方法に準じて行うことができ、例えば、後記実施例に記載の方法等に従って行うことができる。
同様に、本発明におけるSAP130には、配列番号:4で表されるアミノ酸配列において1または2個以上(例えば1~50個程度、好ましくは1~30個程度、より好ましくは1~10個程度、さらに好ましくは1~数(5、4、3もしくは2)個)のアミノ酸が置換、欠失、挿入もしくは付加された(あるいはそれらが組み合わされた)アミノ酸配列を含有する蛋白質も含まれる。また、本発明におけるFcRγには、配列番号:6で表されるアミノ酸配列において、1または2個以上(例えば1~30個程度、好ましくは1~10個程度、より好ましくは1
~数(5、4、3もしくは2)個)のアミノ酸が置換、欠失、挿入もしくは付加された(あるいはそれらが組み合わされた)アミノ酸配列を含有する蛋白質も含まれる。
一方、SAP130は、死細胞から細胞外へ放出されるので、本発明における抗SAP130抗体はSAP130のいずれの領域を認識するものであってもよいが、好ましくは、ミンクルとの相互作用に重要なミンクルの領域、特に、配列番号:2で表されるアミノ酸配列中アミノ酸番号146~150で示されるVEGQW(配列番号:7)あるいは他の哺乳動物のオルソログにおける対応するアミノ酸配列を含む領域との結合に関与する領域を認識する抗体が挙げられる。
ミンクルmRNAの塩基配列と実質的に相補的な塩基配列とは、哺乳動物細胞内の生理的条件下において、該mRNAの標的配列に結合してその翻訳を阻害し得る程度の相補性を有する塩基配列を意味し、具体的には、例えば、該mRNAの塩基配列と完全相補的な塩基配列(すなわち、mRNAの相補鎖の塩基配列)と、オーバーラップする領域に関して、約80%以上、好ましくは約90%以上、より好ましくは約95%以上、最も好ましくは約97%以上の類似性を有する塩基配列である。
本発明における「塩基配列の類似性」は、相同性計算アルゴリズムNCBI BLAST(National Center for Biotechnology Information Basic Local Alignment Search Tool)を用い、以下の条件(期待値=10;ギャップを許す;フィルタリング=ON;マッチスコア=1;ミスマッチスコア=-3)にて計算することができる。
ストリンジェントな条件下とは、例えば、Current Protocols in Molecular Biology, John Wiley & Sons,6.3.1-6.3.6, 1999に記載される条件、例えば、6×SSC(sodium chloride/sodium citrate)/45℃でのハイブリダイゼーション、次いで0.2×SSC/0.1% SDS/50~65℃での一回以上の洗浄等が挙げられるが、当業者であれば、これと同等のストリンジェンシーを与えるハイブリダイゼーションの条件を適宜選択することができる。
(a) ミンクルmRNAに対するアンチセンス核酸
(b) ミンクルmRNAに対するsiRNA
(c) ミンクルmRNAに対するsiRNAを生成し得る核酸
さらに、本発明のアンチセンス核酸は、二本鎖DNAであるミンクル遺伝子と結合して三重鎖(トリプレックス)を形成し、RNAへの転写を阻害し得るもの(アンチジーン)であってもよい。
RNAの糖部のコンフォーメーションはC2'-endo(S型)とC3'-endo(N型)の2つが支配的であり、一本鎖RNAではこの両者の平衡として存在するが、二本鎖を形成するとN型に固定される。したがって、標的RNAに対して強い結合能を付与するために、2'酸素と4'炭素を架橋することにより、糖部のコンフォーメーションをN型に固定したRNA誘導体であるBNA(LNA)(Imanishi, T. et al., Chem. Commun., 1653-9, 2002; Jepsen, J.S. et al., Oligonucleotides, 14, 130-46, 2004)やENA(Morita, K. et al., Nucleosides Nucleotides Nucleic Acids, 22, 1619-21, 2003)もまた、好ましく用いられ得る。
siRNAは、mRNA上の標的配列のセンス鎖およびアンチセンス鎖をDNA/RNA自動合成機でそれぞれ合成し、適当なアニーリング緩衝液中、約90~約95℃で約1分程度変性させた後、約30~約70℃で約1~約8時間アニーリングさせることにより調製することができる。また、siRNAの前駆体となるショートヘアピンRNA(shRNA)を合成し、これをダイサー(dicer)を用いて切断することにより調製することもできる。
また、好ましい一実施態様において、これらの抗体はヒトを投与対象とする医薬品として使用されることから、該抗体は完全ヒト抗体、ヒト化抗体、マウス-ヒトキメラ抗体などであることが好ましく、特に好ましくは完全ヒト抗体である。
後記実施例に示されるとおり、ミンクルとFcRγとの会合には、ミンクルの膜貫通ドメイン中の、哺乳動物種間でよく保存されたアルギニン残基(配列番号:2で表されるアミノ酸配列中アミノ酸番号41で示されるアミノ酸)が重要である。したがって、ミンクルの該アルギニン残基を含む膜貫通領域に特異的に結合し得る物質は、ミンクルとFcRγとの相互作用を有効に阻害し得る。膜貫通領域を標的とする場合は疎水性が要求されるので、脂溶性低分子化合物の利用はきわめて有利である。
ミンクル、SAP130またはFcRγに対する抗体や、ミンクルの発現またはミンクルとSAP130もしくはFcRγとの相互作用を阻害する低分子化合物を含有する医薬は低毒性であり、そのまま液剤として、または適当な剤形の医薬組成物として、ヒトまたは他の哺乳動物(例、マウス、ラット、ウサギ、ヒツジ、ブタ、ウシ、ネコ、イヌ、サルなど)に対して経口的または非経口的(例、血管内投与、皮下投与など)に投与することができる。
投与に用いられる医薬組成物としては、上記の抗体もしくは低分子化合物またはその塩と薬理学的に許容され得る担体、希釈剤もしくは賦形剤とを含むものであってもよい。このような医薬組成物は、経口または非経口投与に適する剤形として提供される。
ミンクルmRNAに対するアンチセンス核酸、siRNA、リボザイムおよびそれらをコードする核酸を含有する医薬は低毒性であり、そのまま液剤として、または適当な剤形の医薬組成物として、ヒトまたは非ヒト哺乳動物(例、マウス、ラット、ウサギ、ヒツジ、ブタ、ウシ、ネコ、イヌ、サルなど)に対して経口的または非経口的(例、血管内投与、皮下投与など)に投与することができる。
これらの核酸を上記の抗炎症剤、炎症性疾患の予防・治療剤などとして使用する場合、自体公知の方法に従って製剤化し、投与することができる。即ち、本発明の核酸を、単独あるいはレトロウイルスベクター、レンチウイルスベクター、アデノウイルスベクター、アデノ随伴ウイルスベクターなどの適当な哺乳動物細胞用の発現ベクターに機能可能な態様で挿入した後、常套手段に従って製剤化することができる。該核酸は、そのままで、あるいは摂取促進のための補助剤とともに、遺伝子銃やハイドロゲルカテーテルのようなカテーテルによって投与することができる。あるいは、エアロゾル化して吸入剤として気管内に局所投与することもできる。
さらに、体内動態の改良、半減期の長期化、細胞内取り込み効率の改善を目的に、前記核酸を単独またはリポソームなどの担体とともに製剤(注射剤)化し、静脈、皮下等に投与してもよい。
したがって、本発明はまた、ミンクルの発現またはミンクルとSAP130もしくはFcRγとの相互作用を調節する物質を選択することによる、炎症反応を調節する物質のスクリーニング方法を提供する。
本発明は、ミンクルもしくはその細胞外領域を含む断片とSAP130とを、被験物質の存在下および非存在下で接触させ、両条件下におけるミンクルもしくはその断片とSAP130との相互作用の程度を比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法を提供する。
本スクリーニング方法に用いられるミンクルおよびSAP130蛋白質は、上記本発明の医薬に関する説明において記載されたとおりのものである。ミンクルはその全長を用いてもよいし、その細胞外領域(配列番号:2で表されるアミノ酸配列にあっては、アミノ酸番号45~219で示されるアミノ酸配列からなる領域)を含む断片を用いてもよい。SAP130蛋白質も、ミンクルとの結合およびミンクルの活性化に関与する領域を含む限り、その断片を用いることができる。以下、特にことわらない限り、ミンクルおよびSAP130という場合、上記の機能的断片を包含する意味で用いることとする。
(a)被験物質と、ミンクルおよびSAP130とを接触させる工程、
(b)被験物質を接触させたミンクルのSAP130との結合活性を測定し、該活性を被験物質を接触させない対照ミンクルのSAP130との結合活性と比較する工程、および
(c)前記(b)の比較結果に基づいて、ミンクルのSAP130との結合活性を調節する被験物質を選択する工程。
b-1)抗ミンクル抗体または抗SAP130抗体を用いて免疫沈降し、免疫沈降で使用しなかった抗体でウェスタンブロッティングを行い、ミンクルとSAP130との結合量を測定する方法。
b-2)ミンクルまたはSAP130のいずれか一方を、ポリヒスチジンもしくはGSTなどの標識との融合蛋白質として発現させ、またはビオチン化させ、ポリヒスチジンはニッケルに、GSTはグルタチオンに、ビオチンはアビジンに結合することから、それらを利用して結合体を回収し、b-1)と同様のウェスタンブロッティングで結合量を測定する方法。
b-3)表面プラズモン共鳴法(ビアコア)。
b-4)蛍光標識したミンクルのSAP130発現細胞への結合をフローサイトメーターで測定する方法。
本発明はまた、被験物質の存在下および非存在下で、ミンクルもしくはその細胞外および膜貫通領域を含む断片とFcRγとを発現する細胞における、ミンクルもしくはその断片とFcRγとの相互作用の程度を測定・比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法を提供する。
本スクリーニング方法に用いられるミンクルおよびFcRγ蛋白質は、上記本発明の医薬に関する説明において記載されたとおりのものである。ミンクルはその全長を用いてもよいし、その細胞外領域および膜貫通領域(配列番号:2で表されるアミノ酸配列にあっては、アミノ酸番号22~219で示されるアミノ酸配列からなる領域)を含む断片を用いてもよい。FcRγ蛋白質も、ミンクルとの結合および細胞内シグナル伝達に関与する領域を含む限り、その断片を用いることができる。以下、特にことわらない限り、ミンクルおよびFcRγという場合、上記の機能的断片を包含する意味で用いることとする。
(a)被験物質、ミンクルおよびFcRγを発現し、それらの相互作用により伝達されるシグナル(「活性化シグナル」という)を測定可能な細胞に接触させる工程、
(b)被験物質を接触させた細胞における活性化シグナルのレベルを測定し、該レベルを被験物質を接触させない対照細胞における活性化シグナルのレベルと比較する工程、および
(c)前記(b)の比較結果に基づいて、炎症反応を調節する被験物質を選択する工程。
細胞、COS7細胞、2B4T細胞、CHO、MCF-7細胞、H295R細胞などの動物細胞をあげることができる。ミンクルおよびFcRγをコードする核酸は、スクリーニング法(I)において上記したと同様にして単離し、宿主細胞内で機能しうるプロモーターを有する発現ベクターに挿入して、例えば、リン酸カルシウム共沈殿法、PEG法、エレクトロポレーション法、マイクロインジェクション法、リポフェクション法などにより、このベクターを宿主細胞に導入することにより作製することができる。
また、活性化シグナルの測定は、上記シグナル伝達経路の活性化によって産生されるMIP-2、TNFα、IL-6、IL-8、IL-12、等の炎症性サイトカイン/ケモカインを、例えば、それらに対する抗体を用いてウェスタンブロッティングやELISA等のイムノアッセイにより、定量することによって行ってもよい。
上記スクリーニング法(II)において、被験物質と細胞との接触を、SAP130の存在下で行うことにより、ミンクルとFcRγとの相互作用を調節する物質に加えて、ミンクルとSAP130との相互作用を調節する物質をスクリーニングすることが可能である。本スクリーニング法でも、同様に、活性化シグナルレベルを低下させた被験物質は、抗炎症性物質、特に炎症性疾患の予防・治療薬の候補として選択される。一方、活性化シグナルレベルを増大させた被験物質は、組織損傷や感染症の治療薬の候補として選択される。選択された物質がミンクルとSAP130、あるいはミンクルとFcRγのいずれの相互作用に影響するかは、例えば、上記スクリーニング法(I)もしくは(II)を併用することにより、確認することができる。
本発明はまた、被験物質の存在下および非存在下で、ミンクルを産生する細胞における該蛋白質またはそれをコードするmRNAの量を測定・比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法を提供する。
(a)被験物質とミンクルの発現を測定可能な細胞とを接触させる工程、
(b)被験物質を接触させた細胞におけるミンクルの発現量を測定し、該発現量を被験物質を接触させない対照細胞におけるミンクルの発現量と比較する工程、
(c)前記(b)の比較結果に基づいて、ミンクルの発現量を減少させる被験物質を選択する工程。
また、ミンクルの発現を測定可能な細胞は、非ヒト哺乳動物より単離したミンクルを産生する組織もしくは臓器、さらには非ヒト哺乳動物個体の形態で提供されうる。あるいは、ミンクル遺伝子の内在プロモーターの制御下にあるレポーター遺伝子を導入したトランスジェニック動物の細胞、組織、臓器もしくは個体であってもよい。
上記の方法以外にも、他の免疫学的手法や表面プラズモン共鳴などを用いて試料中のSAP130量を測定しうることは、当業者に自明であろう。
マウス
C57BL/6 (B6)マウスをClea Japanから購入した。B6バックグラウンドのFcRγ-/- マウスはPark, S.Y. et al., J Clin Invest 102, 1229-38 (1998)に記載されたようにして確立した。CARD9-/-マウスはHara, H. et al., Nat Immunol 8, 619-29 (2007)に記載されたようにして確立し、6回B6と戻し交雑した。B6バックグラウンドのMyD88-/-マウスはS. Akira (Osaka University)からいただいた。FcγRI-/-およびFcγRIII-/-マウスはJ. S. Verbeek (Leiden University)からいただいた。マウスは全てエアーフィルターの層流のある飼育ラック中で維持し、標準の餌および水を自由摂取させた。動物実験は全て我々の施設ガイドラインに従って行った。
ミンクルcDNA はPCRでクローニングし、pMX-IRES-hCD8 vectors 50に挿入した。Mincle-Flagは以前に記載されたものと同じプライマー(Matsumoto, M. et al., J Immunol 163, 5039-48 (1999))を用いて作製した。Ig-Mincle融合タンパク質を構築するために、PCRでマウスミンクルの細胞外ドメイン(アミノ酸 46-214)をhIgG Fcに融合させた。SAP130 cDNAはPCRでクローニングし、pcDNA3.1-V5-His-TOPO (Invitrogen)に挿入した。
ウサギ抗ミンクルポリクローナル抗体はマウスミンクルの細胞質側領域に相当するペプチド(アミノ酸1-16)に対して作製した。抗phospho-Erk Ab はPromega、抗phospho-SykはCell Signaling Technology、抗human IgG-HRPおよびProtein G SepharoseはAmersham Biosciences (Piscataway, NJ)、抗rat IgG-HRPはZymed、抗rat IgG-PEはJackson Immunoresearch、抗Histone-H1 および抗SAP145はSanta Cruz、抗SAP49はAbcam、抗SAP130はNovus Biologicals、SAP155はMBL、抗DDB1はBD Biosciences、そして抗FlagはSigmaから購入した。
チオグリコール酸で誘発した腹膜マクロファージは抗ミンクルおよびマウス抗ラットIgAbsで刺激した。細胞を1% Nonidet P-40溶解緩衝液で溶解し、免疫沈降およびウェスタンブロットは前に記載(Yamasaki, S. et al., Nat Immunol 7, 67-75 (2006))のとおり行った。LPS (L4516)およびzymosan (Z4250)はSIGMAから購入した。
ミンクルの細胞外ドメイン(アミノ酸46-214)は、PCRで終止コドンを欠くhIgG Fc領域のC末端に融合させ、pME18S-SLAMsig-hIgG FcのXhoI/NotI断片に挿入した。293T細胞をpME18S-SLAMsig-hIgG Fc (Ig)またはpME18S-SLAMsig-hIgG Fc-Mincle (Ig-Mincle)で一過的にトランスフェクトした。細胞は無タンパク質培地(PFMH-II)で培養した。ろ過した上清をProtein A-Sepharose columnにアプライし、結合した画分を50mM diethylamineで溶出し、すぐにTris-HCl(pH 7.5)で中和した。主画分をPBSで透析し精製Ig fusion溶液として用いた。タンパク質の分子量および精製度は銀染色および抗hIgG-HRP (Pierce)を用いたウェスタンブロットによって見積もった。Leucine-zipper化Fas-ligand(FasL)はS. Nagata (Kyoto University)からいただいた。
ミンクルの配列はNCBI serverから取得した。79~214残基の範囲のミンクルの部分配列を抽出し、相同性モデリングの一般的方法を用いてその三次元構造を予測した。DC-SIGN (PDB-entry: 1nfd)の結晶構造はProtein Data Bank(PDB)から相同性モデルを生成するための鋳型として取った。ミンクルの部分配列は、NW alignmentを用いて鋳型タンパク質と整列させた。適切なアラインメントを得るべく、ミンクル中のギャップおよびCys残基は鋳型中の対応するCys残基の位置へと手動で置換した。適切なアラインメントを達成し、標的タンパク質中の主鎖の原子をDC-SIGNの鋳型タンパク質中の対応する残基の座標に当てがった。ループ領域中の挿入および欠失を、公知の構造を持つタンパク質の断片から作られた断片データベースから好適な構造を探すことによってモデルにした。Metropolis Monte Carlo法を用いてミンクルモデルのバックボーンに側鎖を構築した。構造を最適化するために、2000段階の最適化を分子動力学パッケージのAMBER8を用いて最急降下法で行った。
ゲノムDNAをDNase (Wako Nippon Gene)処理によって除去した後、reverse transcriptase II (Invitrogen)を用いてランダムプライマーによってcDNA鎖を生成した。遺伝子特異的プライマーを用いることによってリアルタイムPCRによってRNAの発現を定量し、値をβ-actinの発現で正規化した。遺伝子特異的プライマー配列は次のとおりである。
β-actin,
5’-TGGAATCCTGTGGCATCCATGAAAC-3’ (forward)
5’-TAAAACGCAGCTCAGTAACAGTCCG-3’ (reverse);
IL-6,
5’-TTCCATCCAGTTGCCTTCTTGG-3’ (forward)
5’-CTTCATGTACTCCAGGTAG-3’ (reverse);
TLR2,
5’-CAGCTTAAAGGGCGGGTCAGA-3’ (forward)
5’-TGGAGACGCCAGCTCTGGCTC-3’ (reverse);
ミンクル,
5’-GCTCCAGCAGGGAACAATAG-3’ (forward)
5’-GCCCTTTGATGGAATTCAGA-3’ (reverse);および
FcRγ,
5’-CCTTCCCTTCCCTCTACACC-3’ (forward)
5’-AAGGTAAGGCAGGGTGGTCT-3’ (reverse).
統計解析は全て対応のない両側Student’s t 検定を用いて行った。
マウスミンクルを発現する好塩基球性白血病(RBL-2H3)細胞をウィスターラットに免疫して抗ミンクルモノクローナル抗体を樹立した。Mincle-IRES-GFPを発現する2B4細胞を染色することによってクローン化ハイブリドーマの上清をスクリーニングした。3つの独立クローン1B6 (IgG1,κ), 4A9 (IgG1,κ)および6E2 (IgG2c,κ) の特徴を調べ(図1)、本研究に用いた。それぞれのモノクローナル抗体におけるendotoxinのレベルは1 EU/ml (Limulus Color KY Test, Wako)以下だった。モノクローナル抗体のビオチン化はEZ-link biotinylation kit (Pearce)を用いて行った(図1)。
マウス、ラットおよびヒトのミンクルアミノ酸配列のアラインメントから膜貫通ドメイン内に保存されたアルギニン残基があることがわかった(図2a)。他の免疫受容体について書かれているように、この膜貫通部分内の正に帯電した残基の存在によってミンクルがITAMを含むアダプター分子(FcRγ、DAP10、DAP12およびCD3ζ)と相互作用することが示唆される。ミンクルがこれらのサブユニットのうちのいずれかと結合できるかどうか検証するため、ミンクルを、これらのアダプターとともに293Tにトランスフェクトした。新たに確立した抗ミンクル抗体(図1)を用いた免疫沈降およびウェスタンブロット解析により、ミンクルはFcRγと選択的に結合するが、DAP10、DAP12およびCD3ζとは結合しないことがわかった(図2bおよびデータ省略)。重要なことには、内生ミンクルとFcRγとの結合はマウスの腹膜のマクロファージでも明らかであった(図2c)。そして我々はヒトミンクルもFcRγと結合することを確認した(データ省略)。ミンクルとFcRγとの相互作用はミンクルの膜貫通領域内のArg42(R42)残基を通して仲介された。なぜなら相互の免疫沈降によって証明されたように(図2d)、R42I(正の帯電から中性への)変異でFcRγとの結合が無くされるからである。この結合は、ミンクルがシグナルを伝達するのに重要らしい。というのは、ミンクルおよびFcRγをT細胞ハイブリドーマに異所的に発現させると、ミンクルの架橋によって誘導されたIL-2産生がR42に依存したからである(図2e)。ミンクルにはその細胞質側領域に潜在的なセリン/トレオニンリン酸化部位があるが、C末端側尾部を欠くミンクルの欠損変異体(MincleΔ2-18)は同様の系でのシグナル伝達能力を減じなかった(データ省略)。これらの結果から、ミンクルはFcRγを通したシグナル伝達ができることが示唆された。
次に、内生ミンクルが活性化シグナルを変換できるかどうか検証するために、チオグリコール酸で誘導した腹膜のマクロファージを抗ミンクル抗体で刺激した。固定した抗ミンクルによりTNFα、MIP-2(CXCL2)図3a)、KC(CXCL1)およびIL-6(データ省略)の産生が誘導されたが対照IgGではされなかった。ミンクル誘導性の炎症性サイトカインの産生はFcRγ-/-細胞ではなかったが、FcRγ非依存性LPS刺激で匹敵する量のサイトカインが誘導された(図3b)。TLRシグナル伝達に重要なアダプターのMyD88はミンクルを介したサイトカイン産生には必須ではなかった(図3b)。従って、ミンクルはFcRγ依存的に活性化シグナルを変換してマクロファージに伝えるということになる。
ミンクルの表面での発現にはFcRγは本質的に必要ではない(データ省略)が、LPS誘導性の内生ミンクルの表面発現の亢進はFcRγ-/- BMMφでは野生型よりも弱かった。しかしながら、興味深いことに、この上昇はMyD88非依存性であることが見出された(図4)。
次に、我々はミンクルの生理学的リガンドを発見しようとした。骨髄性細胞による炎症性サイトカインおよびケモカインの分泌はリガンド候補のスクリーニングに用いられ得る可能性のある指標である。しかしながら、そのようなサイトカインおよびケモカインはTLR刺激に際しても大量に産生される。従って推定上のミンクルのリガンドをコンタミする可能性のあるTLRのリガンドと区別するために、我々は非骨髄性T細胞ハイブリドーマを宿主細胞として用い、そしてNFAT-GFPレポーターをITAM介在性シグナルの特異的検出手段として利用した。
死細胞由来のミンクルリガンドを更に調べるために、我々は可溶性ミンクルタンパク質を構築した。ミンクルはII型膜タンパク質であることから、ミンクルの細胞外ドメインをヒトイムノグロブリンG Fcドメインに融合させた(Ig-Mincle) (図6a)。我々ははじめにIg-Mincleが死細胞を特異的に認識するかどうか検証した。Ig-MincleはAnnexinV+PI+の胸腺(図6b)および2B4死細胞(データ省略)に選択的に結合したが、対照Igはしなかった。従って、死細胞がミンクル結合タンパク質を発現しているようである。
)のいずれとも相互作用しなかった。これらの結果から、SAP130がミンクルに選択的に結合することが示された。
2B4T細胞ハイブリドーマは死細胞を生成するために4日間培養した。1×108の細胞を1% NP-40 溶解緩衝液(1% NP-40, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 10μg/ml aprotinin, 12.5μg/ml chymostatin, 50μg/ml leupeptin, 25μg/ml pepstatin A, 1 mM phenylmethylsulfonyl fluoride)で溶解した。IgおよびIg-Mincleタンパク質はdimethyl pimelimidate (Pierce)およびethanolamineを用いてProtein G Sepharose 4 Fast Flow (Amersham Bioscience)に共有結合させた。細胞ライセートはProteinG Sepharoseを通して2回溶出させ、次いでIg-coupled ProteinG Sepharoseを通して3回溶出させた。フロースルー画分はIg-Mincle-bound ProteinG Sepharose columnにアプライし、カラムを溶解緩衝液で洗浄した。結合画分は試料緩衝液と煮沸することによって溶出し、SDS-PAGEで分離し、続いてPVDFに転写してColloidal Gold Total Protein Stain (Bio-Rad)で染色した。p130に相当するバンドを切り出してMALDI-TOF/MS in Protein Research Network, Inc.で解析した(図7)。
次に我々は精製SAP130がミンクル発現細胞を活性化できるかどうか検証した。哺乳動物細胞から組み換えSAP130を精製するために、293T細胞でV5タグ付きSAP130を発現させ、抗V5-アガロースを用いてV5ペプチドとともに溶出して細胞ライセートから精製した。プレートにコーティングした抗V5上でSAP130-V5で腹膜マクロファージを刺激すると、相当量のMIP-2が上清中に分泌された(図8a)。同様の刺激によりミンクルおよびFcRγを発現するT細胞ハイブリドーマからIL-2産生も誘導された(図8b)。このことにより、精製タンパク質の活性がコンタミしたエンドトキシンのせいである可能性は極端に小さくなった。我々はSAP-130-V5がミンクルを発現しない親細胞には何ら影響を及ぼさないことも確認した(図8b)。更に、ミンクル発現細胞によるSAP130-V5誘発性IL-2産生が可溶性抗ミンクルモノクローナル抗体によってほぼ完全に阻害された(図8b)。これらの結果によりSAP130がミンクルの内生リガンドとして作用できることが示唆される。
最後に、我々はin vivoでミンクルの生理学的機能について調べた。いくつかの報告で、過剰または非恒常性細胞死により感染が無いにもかかわらず炎症性細胞の一過的な浸潤が誘導されることが証明された。この現象を研究するためのモデル系にはマウスの全身放射線照射が含まれるが、これは、皮質領域中でCD4+CD8+二重陽性(DP)胸腺細胞の大量死を誘導し(図9a、b)、且つ結果的に好中球の胸腺への一過的浸潤を誘起する(図9b、右パネル)。p53-/-マウス等のDP胸腺細胞死が起きない変異マウスでは浸潤が減じられることが報告されているので、この好中球の浸潤は過剰な細胞死の結果のようだ。我々は、DP胸腺細胞を欠くRag2-/-マウス(データ省略)同様アポトーシス抵抗性のApaf1-/-マウスでは照射後、好中球の浸潤がずっと少ないことも確認している。
dexamethazone誘導性の胸腺細胞死による好中球の浸潤も、抗ミンクルモノクローナル抗体処理により減じられた(図10)。モノクローナル抗体クローン1B6の、好中球浸潤への阻止効果はクローン4A9のそれよりもより強力であったが、これはin vitroでの1B6のミンクルへのより強力な阻止効果と一致する(図5b)。
抗ミンクルはLPS刺激による好中球のin vivo輸送に影響しなかった(図11)。従って、胸腺細胞死に際した好中球の浸潤には、その大半にミンクルが介在する。
様々な自己および非自己リガンドを認識するため、C型レクチン受容体は重要な免疫受容体であることを示す証拠が増えている。C型レクチンによって認識される病原体成分はよく書かれてきているが、自己リガンドはそれほどよくわかってはいない。大まかに言えば、それらは組織損傷に関連した分子のように思える。例えば、エンドサイトーシス受容体のMBL、Lox-1およびMGL-1は死細胞からのリガンドを認識し、それらの一掃に関与し得る。抗ミンクルモノクローナル抗体は胸腺死細胞の食作用を阻止しなかったことから、ミンクルはエンドサイトーシス受容体ではないように思える(図12)。これまで損傷した自己を認識するとわかったものは無いが、あるレクチン受容体はITAMを通したシグナル伝達に介在できる。従ってミンクルは死細胞を直接認識する初のITAM共役性受容体である。
我々はSAP130をミンクルのリガンドとして同定した。U2 snRNP複合体内で、SAP130はSAP145、SAP155およびSAP49と相互作用してスプライソソームを形成する(図13a)。従って、SAP155、SAP145およびSAP49もIg-Mincleとともに共沈殿するが、SAP130ほど効率はよくない(図13b)。精製SAP130を用いた我々のデータは、それがミンクル発現細胞を独力で活性化することを示唆するが、複合体形成がミンクルの反応性を亢進するかどうかは現時点で不明である。
Claims (18)
- ミンクルの発現またはミンクルとSAP130もしくはFcRγとの相互作用を阻害する物質を含有してなる抗炎症剤。
- ミンクルとSAP130との相互作用を阻害する物質がミンクルに対する抗体である、請求項1に記載の剤。
- 抗体が、配列番号:2で表されるヒトミンクルのアミノ酸配列中アミノ酸番号146~150で示されるアミノ酸配列もしくは他の哺乳動物のオルソログにおける対応するアミノ酸配列を認識する、請求項2に記載の剤。
- ミンクルとSAP130との相互作用を阻害する物質が、配列番号:2で表されるヒトミンクルのアミノ酸配列中アミノ酸番号146~150で示されるアミノ酸配列もしくは他の哺乳動物のオルソログにおける対応するアミノ酸配列を含むペプチドである、請求項1に記載の剤。
- ミンクルとSAP130との相互作用を阻害する物質が、SAP130に対する抗体である、請求項1に記載の剤。
- ミンクルの発現を阻害する物質が、ミンクル遺伝子に対するアンチセンス核酸、リボザイムまたはsiRNAである、請求項1に記載の剤。
- ミンクルとFcRγとの相互作用を阻害する物質が、ミンクルおよび/またはFcRγに対する抗体である、請求項1に記載の剤。
- ミンクルとFcRγとの相互作用を阻害する物質が、ミンクルの膜貫通ドメイン中の保存されたアルギニン残基を含む部位に結合する、請求項1に記載の剤。
- 炎症性疾患の予防および/または治療のための、請求項1~8のいずれか1項に記載の剤。
- ミンクルもしくはその細胞外領域を含む断片とSAP130とを、被験物質の存在下および非存在下で接触させ、両条件下におけるミンクルもしくはその断片とSAP130との相互作用の程度を比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法。
- 被験物質の存在下および非存在下で、ミンクルもしくはその細胞外および膜貫通領域を含む断片とFcRγとを発現する細胞における、ミンクルもしくはその断片とFcRγとの相互作用の程度を測定・比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法。
- ミンクルおよびFcRγを介するシグナル伝達経路の活性化を指標として、ミンクルもしくはその断片とFcRγとの相互作用の程度を比較する、請求項11に記載の方法。
- ミンクルおよびFcRγを介するシグナル伝達により活性化される転写因子が結合し得る塩基配列を含むプロモーターの制御下にある遺伝子の発現を指標とする、請求項12に記載の方法。
- さらにSAP130を共存させることを特徴とする、請求項11~13のいずれか1項に記載の方法。
- 被験物質の存在下および非存在下で、ミンクルを産生する細胞における該蛋白質またはそれをコードするmRNAの量を測定・比較することを特徴とする、炎症反応を調節する物質のスクリーニング方法。
- さらにSAP130を共存させることを特徴とする、請求項15に記載の方法。
- 抗炎症作用を有する物質の選択のための、請求項10~16のいずれか1項に記載の方法。
- 被験動物より採取した試料中のSAP130量を測定することを特徴とする、非恒常性細胞死の検出方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09798008A EP2347768A4 (en) | 2008-07-17 | 2009-07-17 | NEW APPLICATION OF THE RECIPE RECOGNIZED BY SUGAR CHAIN |
AU2009271970A AU2009271970A1 (en) | 2008-07-17 | 2009-07-17 | Novel use application of sugar chain-recognizing receptor |
CN2009801367301A CN102170910A (zh) | 2008-07-17 | 2009-07-17 | 糖链识别受体的新用途 |
CA2736311A CA2736311A1 (en) | 2008-07-17 | 2009-07-17 | Novel use application of sugar chain-recognizing receptor |
US13/054,556 US8440187B2 (en) | 2008-07-17 | 2009-07-17 | Use application of sugar chain-recognizing receptor |
JP2010520914A JP5413915B2 (ja) | 2008-07-17 | 2009-07-17 | 糖鎖認識受容体の新規用途 |
ZA2011/01204A ZA201101204B (en) | 2008-07-17 | 2011-02-15 | Novel use application of sugar chain-recognizing receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008186570 | 2008-07-17 | ||
JP2008-186570 | 2008-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010008084A1 true WO2010008084A1 (ja) | 2010-01-21 |
Family
ID=41550484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/063008 WO2010008084A1 (ja) | 2008-07-17 | 2009-07-17 | 糖鎖認識受容体の新規用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8440187B2 (ja) |
EP (1) | EP2347768A4 (ja) |
JP (1) | JP5413915B2 (ja) |
KR (1) | KR20110050639A (ja) |
CN (1) | CN102170910A (ja) |
AU (1) | AU2009271970A1 (ja) |
CA (1) | CA2736311A1 (ja) |
RU (1) | RU2011105818A (ja) |
WO (1) | WO2010008084A1 (ja) |
ZA (1) | ZA201101204B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015159766A (ja) * | 2014-02-27 | 2015-09-07 | 国立大学法人京都大学 | クッシング症候群の検査方法、検査用バイオマーカー及び治療剤 |
CN113563480A (zh) * | 2021-07-12 | 2021-10-29 | 中国科学院武汉病毒研究所 | 一种cld蛋白突变体及应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117130035A (zh) * | 2017-08-18 | 2023-11-28 | 南京中硼联康医疗科技有限公司 | 生物剂量计及具有其的中子捕获治疗系统 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001112482A (ja) * | 1999-10-15 | 2001-04-24 | Japan Science & Technology Corp | 新規c型レクチンおよびその遺伝子 |
WO2006105252A2 (en) * | 2005-03-28 | 2006-10-05 | The Regents Of The University Of Colorado | Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells |
JP2008186570A (ja) | 2007-01-26 | 2008-08-14 | Samsung Electronics Co Ltd | サーボ同期パターンの形成方法、書き込みエラー防止方法、及びハードディスクドライブ装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019860A1 (en) * | 1999-10-15 | 2005-01-27 | Japan Science And Technology Corporation | Novel C-type lectin and gene thereof |
US20070160578A1 (en) * | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
CA2722173A1 (en) * | 2008-04-22 | 2009-10-29 | The Rockefeller University | Methods of identifying anti-inflammatory compounds |
-
2009
- 2009-07-17 US US13/054,556 patent/US8440187B2/en not_active Expired - Fee Related
- 2009-07-17 JP JP2010520914A patent/JP5413915B2/ja active Active
- 2009-07-17 CA CA2736311A patent/CA2736311A1/en not_active Abandoned
- 2009-07-17 KR KR1020117003667A patent/KR20110050639A/ko not_active Application Discontinuation
- 2009-07-17 RU RU2011105818/15A patent/RU2011105818A/ru unknown
- 2009-07-17 AU AU2009271970A patent/AU2009271970A1/en not_active Abandoned
- 2009-07-17 WO PCT/JP2009/063008 patent/WO2010008084A1/ja active Application Filing
- 2009-07-17 CN CN2009801367301A patent/CN102170910A/zh active Pending
- 2009-07-17 EP EP09798008A patent/EP2347768A4/en not_active Withdrawn
-
2011
- 2011-02-15 ZA ZA2011/01204A patent/ZA201101204B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001112482A (ja) * | 1999-10-15 | 2001-04-24 | Japan Science & Technology Corp | 新規c型レクチンおよびその遺伝子 |
WO2006105252A2 (en) * | 2005-03-28 | 2006-10-05 | The Regents Of The University Of Colorado | Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells |
JP2008186570A (ja) | 2007-01-26 | 2008-08-14 | Samsung Electronics Co Ltd | サーボ同期パターンの形成方法、書き込みエラー防止方法、及びハードディスクドライブ装置 |
Non-Patent Citations (24)
Title |
---|
"Current Protocols in Molecular Biology", 1999, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 1310 |
HARA, H ET AL., NAT IMMUNOL, vol. 8, 2007, pages 619 - 29 |
IMANISHI, T ET AL., CHEM. COMMUN., 2002, pages 1653 - 9 |
J CLIN INVEST, vol. 108, 2001, pages 957 - 62 |
J IMMUNOL, vol. 163, 1999, pages 5039 - 48 |
JEPSEN, J.S. ET AL., OLIGONUCLEOTIDES, vol. 14, 2004, pages 130 - 46 |
KARLIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877 |
KITAMURA,K. ET AL.: "Critical role of the Fc receptor gamma-chain on APCs in the development of allergen-induced airway hyperresponsiveness and inflammation", J IMMUNOL, vol. 178, no. 1, 2007, pages 480 - 488, XP008142988 * |
MATSUMOTO, M ET AL., J IMMUNOL, vol. 163, 1999, pages 5039 - 48 |
MATSUMOTO, M. ET AL.: "A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages", J IMMUNOL, vol. 163, no. 9, 1999, pages 5039 - 5048, XP002935414 * |
MORITA, K ET AL., NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS, vol. 22, 2003, pages 1619 - 21 |
MYERS; MILLER, CABIOS, vol. 4, 1988, pages 11 - 17 |
NAT IMMUNOL, vol. 7, 2006, pages 1258 - 65 |
NAT REV IMMUNOL, vol. 6, 2006, pages 823 - 35 |
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453 |
ONCOGENE, vol. 20, 2001, pages 7085 - 95 |
PARK, S.Y ET AL., J CLIN INVEST, vol. 102, 1998, pages 1229 - 38 |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 - 2448 |
See also references of EP2347768A4 |
WELLS,C.A. ET AL.: "The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans", J IMMUNOL, vol. 180, no. 11, June 2008 (2008-06-01), pages 7404 - 7413, XP008142987 * |
YAMASAKI, S ET AL., NAT IMMUNOL, vol. 7, 2006, pages 67 - 75 |
YAMASAKI, S. ET AL.: "Mincle is an ITAM-coupled activating receptor that senses damaged cells", NAT IMMUNOL, vol. 9, no. 10, October 2008 (2008-10-01), pages 1179 - 1188, XP008142990 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015159766A (ja) * | 2014-02-27 | 2015-09-07 | 国立大学法人京都大学 | クッシング症候群の検査方法、検査用バイオマーカー及び治療剤 |
CN113563480A (zh) * | 2021-07-12 | 2021-10-29 | 中国科学院武汉病毒研究所 | 一种cld蛋白突变体及应用 |
Also Published As
Publication number | Publication date |
---|---|
US8440187B2 (en) | 2013-05-14 |
KR20110050639A (ko) | 2011-05-16 |
JP5413915B2 (ja) | 2014-02-12 |
RU2011105818A (ru) | 2012-08-27 |
EP2347768A4 (en) | 2012-06-06 |
EP2347768A1 (en) | 2011-07-27 |
JPWO2010008084A1 (ja) | 2012-01-05 |
CN102170910A (zh) | 2011-08-31 |
ZA201101204B (en) | 2012-05-30 |
CA2736311A1 (en) | 2010-01-21 |
US20110177084A1 (en) | 2011-07-21 |
AU2009271970A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11359020B2 (en) | Agents that modulate immune cell activation and methods of use thereof | |
US8153121B2 (en) | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders | |
US11485787B2 (en) | Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof | |
TR201802838T4 (tr) | Anti-folat reseptör alfa antikorlar ve bunların kullanımı. | |
JPWO2008032876A1 (ja) | Er陰性およびher2陰性である乳癌の予防または治療剤およびそのスクリーニング方法 | |
JP2008502368A (ja) | Siglec−6関連疾患の診断および処置 | |
JP7175526B2 (ja) | 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価 | |
JP6113721B2 (ja) | 治療標的及び診断標的 | |
JP5413915B2 (ja) | 糖鎖認識受容体の新規用途 | |
JP2011520781A (ja) | 治療、診断及び検査のためのms4a12を伴う方法、及びms4a12を標的とする剤 | |
JP6226315B2 (ja) | 炎症性疾患の予防・治療剤、並びに炎症性疾患予防・治療薬のスクリーニング方法 | |
WO2016031996A1 (ja) | 関節炎の予防·治療剤、検査キット、並びに関節炎予防·治療薬のスクリーニング方法 | |
KR102401005B1 (ko) | 고위험군 자궁내막증의 예방 또는 치료용 조성물 | |
JP6846808B2 (ja) | Card14を用いた治療、診断およびスクリーニング | |
JP2010111623A (ja) | 糖鎖認識受容体の新規用途 | |
Class et al. | Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV | |
US20090274696A1 (en) | Methods for treating inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980136730.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09798008 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010520914 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009798008 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117003667 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009271970 Country of ref document: AU Ref document number: 2011105818 Country of ref document: RU Ref document number: 721/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2736311 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009271970 Country of ref document: AU Date of ref document: 20090717 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13054556 Country of ref document: US |